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The Canadian Network for Mood and Anxiety Treatments published
guidelines for the management of bipolar disorder in 2005, with
updates in 2007 and 2009. This third update, in conjunction with the
International Society for Bipolar Disorders, reviews new evidence and
is designed to be used in conjunction with the previous publications.
The recommendations for the management of acute mania remain
largely unchanged. Lithium, valproate, and several atypical
antipsychotic agents continue to be ﬁrst-line treatments for acute
mania. Monotherapy with asenapine, paliperidone extended release
(ER), and divalproex ER, as well as adjunctive asenapine, have been
added as ﬁrst-line options.
For the management of bipolar depression, lithium, lamotrigine, and
quetiapine monotherapy, as well as olanzapine plus selective serotonin
reuptake inhibitor (SSRI), and lithium or divalproex plus
SSRI ⁄ bupropion remain ﬁrst-line options. Lurasidone monotherapy
and the combination of lurasidone or lamotrigine plus lithium or
divalproex have been added as a second-line options. Ziprasidone alone
or as adjunctive therapy, and adjunctive levetiracetam have been added
as not-recommended options for the treatment of bipolar depression.
Lithium, lamotrigine, valproate, olanzapine, quetiapine,
aripiprazole, risperidone long-acting injection, and adjunctive
ziprasidone continue to be ﬁrst-line options for maintenance treatment
of bipolar disorder. Asenapine alone or as adjunctive therapy have been
added as third-line options.
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Section 1. Introduction

In 2005, the Canadian Network for Mood and
Anxiety Treatments (CANMAT) published guidelines for the management of bipolar disorder (BD)
(1), followed by updates in early 2007 (2) and in
2009 [in collaboration with the International
Society for Bipolar Disorders (ISBD)] (3). This
update includes data published in 2009 through
early 2012, and is designed to be used in conjunction with the 2005 CANMAT guidelines and
previous updates (1–3).
The purpose of this update is to add previously
unpublished material to the guidelines. This update
is designed to be used with the previous iterations of
the guidelines. As in the previous updates, the guidelines are divided into eight sections (Table 1.0) and
the same numbering system has been used for the
sections and tables in order to facilitate ease of use.
New evidence is incorporated into the management
recommendations, and changes to the recommendation tables have been clearly denoted with bold
italics and a footnote, and have been described
in the text. The objective is to ensure that the
CANMAT guidelines for treatment of BD remain
current and useful for the practicing clinician.
Central to this update are the tables showing
ﬁrst-line, second-line, third-line, and not-recommended treatment options. These tables may assist
in the selection of treatment, while the text of this
update and the previous guideline iterations
provide the details of the evidence that was used
to make the recommendations. Similarly, the
treatment algorithms condense key management
information into a decision-tree ﬂow-chart; the
clinician should begin by positioning the patient in
the decision tree, and then follow the arrows for
subsequent management suggestions.
Search strategies and methods to assess evidence
were as described in the original guidelines (1).
Evidence available only in abstract form was also
considered in order to ensure that the recommen-

dations are as up to date as possible. The criteria
for rating strength of evidence and making a
clinical recommendation are shown in Tables 1.1
and 1.2.
We caution the readers that the evidence-based
guidelines are limited by the data that are available. For instance, drugs that have patents are
likely to have been more widely studied and their
design was likely inﬂuenced by the goals of the
sponsor to obtain approval. Generic drugs,
although may be useful, may not have been widely
studied because of lack of sponsorship, thus
aﬀecting their placement in the treatment algorithm. Finally, it is important to understand that
the lack of evidence for a particular drug does not
imply ineﬃcacy or eﬃcacy. Clinicians must exercise
caution and choose treatments based on a careful
risk–beneﬁt analysis for each situation.
Section 2. Foundations of management

Epidemiology

Prevalence. The World Mental Health Survey
Initiative, involving 61392 people in nine countries
in North and South America, Europe, and Asia,
reported lifetime (and 12-month) prevalence estimates of 0.6% (0.4%) for BD I, 0.4% (0.3%) for
BD II, and 1.4% (0.8%) for subthreshold BD (4).
However, there were large cross-national diﬀerences in rates, with the lifetime rates ranging from
0 to 1% for BD I, 0 to 1.1% for BD II, and 0.1 to
2.4% for subthreshold BD.
In the Canadian Community Health Survey–
Mental Health and Well-Being (CCHS 1.2), the
prevalence of BD was signiﬁcantly lower among

Table 1.1. Evidence criteria
1
2
3

Table 1.0. Overview of guideline sections
4
Section 1. Introduction
Section 2. Foundations of management
Section 3. Acute management of bipolar mania
Section 4. Acute management of bipolar depression
Section 5. Maintenance therapy for bipolar disorder
Section 6. Special populations
Section 7. Acute and maintenance management of bipolar II
disorder
Section 8. Safety and monitoring
Closing statement
Disclosures
References

2

Meta-analysis or replicated double-blind (DB), randomized
controlled trial (RCT) that includes a placebo condition
At least one DB-RCT with placebo or active comparison
condition
Prospective uncontrolled trial with at least ten or more
subjects
Anecdotal reports or expert opinion

Table 1.2. Treatment recommendation
First line
Second line
Third line
Not recommended

Level 1 or level 2 evidence plus clinical
support for efficacy and safety
Level 3 evidence or higher plus clinical
support for efficacy and safety
Level 4 evidence or higher plus clinical
support for efficacy and safety
Level 1 or level 2 evidence for lack
of efficacy
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immigrant, compared to non-immigrant, subjects,
but immigrants with BD were signiﬁcantly less
likely to report contact with mental health professionals (5).
Impact. A meta-analysis of 15 studies identiﬁed a
high prevalence of lifetime suicide attempts both in
patients with BD I (36.3%) and in those with BD II
(32.4%) (6). In the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD)
(n = 4360), the completed suicide rate was 0.014
per 100 person-years (7). A large cohort study
found that among men, the absolute risk of suicide
was highest with BD (7.8%) compared to any
other psychiatric condition, and among women,
BD was associated with the second highest risk, at
4.8%, just below schizophrenia at 4.9% (8). Claims
database data demonstrate the signiﬁcant economic impact of suicide attempts, with one-year
healthcare costs in the period post-attempt being
more than double those in the year prior to an
attempt (9).
The large, two-year, prospective, observational
European Mania in Bipolar disorder Longitudinal Evaluation of Medication (EMBLEM) study
(n = 2289) found high work impairment in 69%
of patients at baseline and 41% at two years
(10). Rapid cycling, high baseline work impairment, lower levels of education, recent admissions, mania symptom severity, and overall
severity all predicted higher work impairment,
while living in a relationship and independent
housing predicted lower work impairment at
follow-up. Similarly, the Understanding PatientsÕ
Needs, Interactions, Treatment, and Expectations
(UNITE) global survey (n = 1300) revealed that
only one-third of patients with BD were employed full-time (11). In the UNITE survey,
treatment of depression, weight gain, and quality
of life were identiﬁed by patients with BD as
aspects of care most in need of improvement
(11).
A meta-analysis of data from 12 trials
(n = 1838) found that the self-esteem of patients
with remitted BD was signiﬁcantly lower than that
of controls but signiﬁcantly higher than that of
patients with remitted major depressive disorder
(MDD) (12). In addition, self-esteem may follow a
ﬂuctuating course during remission of BD.
In a health claims database, risk of arrest was
associated with substance use, poor reﬁll compliance, and prior arrest (13). Among patients treated
with an atypical antipsychotic agent, there was a
lower risk of arrest in those who had frequent
outpatient visits (approximately monthly) compared to those who did not.

Course. In a sub-analysis of 771 patients in the
two-year EMBLEM study, approximately one in
three presented with a mixed episode, which was
associated with a lower likelihood of recovery and
greater use of antidepressant therapy compared to
a pure manic state during follow-up (14). The
Systematic Treatment Optimization Program for
Early Mania (STOP-EM) project followed 53
patients presenting with a ﬁrst episode of mania,
and found that more than half experienced recurrence of a mood episode during the one-year
follow-up, with a mean time to event of
7.9 months (15). The mean duration of mood
episodes in BD I, in a longitudinal analysis of 219
patients followed for up to 25 years, was found to
be 13 weeks (16).
Diagnostic assessment

The proposed ﬁfth edition of the Diagnostic and
Statistical Manual of Mental Disorders (DSM-5) is
scheduled to be completed by mid-2013. Revisions
suggested by the International Society for Bipolar
Disorders Diagnostic Guidelines Task Force (17)
were summarized in the previous update to these
guidelines (3). DSM-5 will have separate chapters
for bipolar and related conditions, and depressive
disorders. The condition ÔBD not otherwise speciﬁedÕ (NOS) has been replaced with Ôbipolar
conditions not elsewhere classiﬁedÕ. Substanceinduced BD and BD associated with a general
medical condition have been added.
In the criteria for a manic episode, Ôabnormally
and persistently increased activity or energyÕ has
been added to criterion A, which previously
referred only to a distinct period of abnormally
and persistently elevated, expansive, or irritable
mood. A manic episode emerging during antidepressant treatment can qualify as a manic episode
of BD, provided that the symptoms persisted
beyond the physiological eﬀects of treatment. The
Ômixed episodeÕ diagnosis has been replaced with a
Ômixed featuresÕ speciﬁer, requiring three symptoms
of the opposite pole, which would apply to manic,
hypomanic, and depressive episodes (18). In addition, dimensional speciﬁers for anxiety and suicide
risk have also been proposed.
Chronic disease management

BD is a chronic illness and patients require longterm multi-disciplinary management as described
in the 2005 guidelines (1). A small, cluster-randomized controlled trial (RCT) examined the eﬀect
of community mental health teams (n = 23) who
received enhanced training in relapse prevention
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versus treatment-as-usual (TAU) in 96 patients
with BD (19). The median survival time of patients
treated by the trained teams was prolonged by
8.5 weeks compared to those receiving TAU
(42 weeks versus 33.5 weeks). A collaborative care
model including clinician support through the use
of simpliﬁed guidelines was found to result in
signiﬁcantly greater guideline-concordant therapy
over a three-year follow-up period compared to
TAU in patients with BD (n = 306) (20).
Data suggest that use of a symptom checklist can
substantially increase the recognition of early
warning signs for depressive or manic relapse
(21). There was a positive correlation between the
frequency of monitoring and social ⁄ occupational
functioning.
Psychosocial interventions

When used as adjuncts to pharmacotherapy, psychosocial interventions such as group psychoeducation, cognitive behavior therapy (CBT), and
interpersonal and social rhythm therapy (IPSRT)
have demonstrated signiﬁcant beneﬁts, both in the
treatment of acute depressive episodes and also
as long-term maintenance treatment, including
decreased relapse rates, mood ﬂuctuations, need
for medications, and hospitalizations, as well as
increased functioning and medication adherence
(1–3). Therefore, providing psychological treatments –and, in particular, brief psychoeducation,
which has been demonstrated to be as eﬀective as
CBT at much lower cost (22) – is an essential
aspect of managing patients with BD.
A family-focused treatment approach designed to
help caregivers improve illness management skills
and their own self-care was shown to eﬀectively
reduce depressive symptoms and health-risk behavior among caregivers and family members, and
reduce depressive symptoms in patients (23).
The availability of internet-based strategies has
grown substantially, with demonstrated eﬃcacy in
reducing depressive symptoms and improving psychological quality of life (24–27).
Section 3. Acute management of bipolar mania

Emergency management of acute mania

The acutely manic bipolar patient may present in
an agitated state that acts as a barrier to therapy,
interrupts the physician–patient alliance, and
creates a disruptive, even hazardous, environment. Whenever possible, oral therapy should be
oﬀered ﬁrst, as evidence suggests that oral agents
can be as eﬀective as intramuscular agents (28,
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29). Intramuscular injections oﬀer an alternative
when oral therapy cannot be reliably administered.
Based on current data, the oral atypical antipsychotic agents, risperidone (level 2) (29, 30),
olanzapine (level 2) (30), and quetiapine (level 3)
(30, 31), should be considered ﬁrst in the treatment
of acute agitation. In patients who refuse oral
medications, intramuscular olanzapine (level 2)
(32–35), ziprasidone (level 2) (35–38), and aripiprazole (level 2) (39) or a combination of intramuscular haloperidol and a benzodiazepine should
be considered (level 2) (29, 35, 38, 40, 41). In
general, benzodiazepines should not be used as
monotherapy, but are useful adjuncts to sedate
acutely agitated patients (1).
New data also support the use of intravenous
sodium valproate (level 3) (42) and oral divalproex
ER (level 3) (31) for rapid improvement of acute
mania.
Pharmacological treatment of manic episodes

Pharmacological management of acute manic episodes should follow the algorithm outlined in
Figure 3.1 (1–3). New clinical trial data, and the
availability of several agents, justify some changes
to the recommendations. Monotherapy with asenapine, paliperidone ER, and divalproex ER, as well
as adjunctive asenapine, have been added as ﬁrstline options (Table 3.3).
Step 1. Review general principles and assess medication status: Recommendations from 2005 guidelines remain unchanged.
Step 2. First-line therapies: A comprehensive metaanalysis of 68 trials supported the eﬃcacy of
pharmacotherapy for the treatment of acute mania
(43). Lithium, divalproex, risperidone ER, paliperidone ER, olanzapine, quetiapine, aripiprazole,
ziprasidone, and asenapine (ﬁrst line), carbamazepine, and haloperidol (second line), were signiﬁcantly more eﬀective than placebo, whereas
gabapentin, lamotrigine, and topiramate were not
(not recommended) (43). Haloperidol was more
eﬀective than a number of antimanic agents but
not olanzapine or risperidone, both of which were
more eﬀective than valproate, ziprasidone, and
lamotrigine. Two other recent meta-analyses also
support the eﬃcacy of lithium ⁄ divalproex and
atypical antipsychotic agents for the treatment of
acute mania (44, 45).
Lithium ⁄ divalproex. The eﬃcacy of lithium and
divalproex in the management of acute mania is

CANMAT guidelines for bipolar disorder
Assess safety/functioning
Establish treatment setting
D/C antidepressants
Rule out medical causes
D/C caffeine, alcohol, and illicit substances
Behavioural strategies/rhythms, psychoeducation

Step 1
Review general
principles
&
assess medication
status
+

Step 2
Initiate/optimize,
check compliance

On first-line agent

Not on medication
or first-line agent
Initiate Li, DVP,
AAP, or 2-drug
combination

Lithium or
DVP

AAP

2-drug combination
(Li or DVP + AAP)

No response

Step 3
Add-on or
switch therapy

Add or
switch to AAP

Add or switch to
Li or DVP

Replace one or both
agents with other
first-line agents

No response

Step 4
Add-on or
switch therapy
No response

Replace
p
one or both
agents with other
first-line agents

Step 5
Add-on novel or
experimental agents

Consider adding or
switching to second or
third-line agent or ECT
Consider adding novel
or experimenta
i
l agent

Fig. 3.1. Treatment algorithm for acute mania. Novel ⁄ experimental agents: zotepine, levetiracetam, phenytoin, mexiletine, omega-3fatty acids, calcitonin, rapid tryptophan depletion, allopurinol, amisulpride, folic acid, memantine. D ⁄ C = discontinue;
Li = lithium; DVP = divalproex; AAP = atypical antipsychotic agent.

Table 3.3. Recommendations for pharmacological treatment of acute mania
First line

Monotherapy: lithium, divalproex, divalproex ER a, olanzapineb, risperidone, quetiapine,
quetiapine XR, aripiprazole, ziprasidone, asenapine a, paliperidone ER a
Adjunctive therapy with lithium or divalproex: risperidone, quetiapine, olanzapine, aripiprazole, asenapine a

Second line

Monotherapy: carbamazepine, carbamazepine ER, ECT, haloperidol a
Combination therapy: lithium + divalproex

Third line

Monotherapy: chlorpromazine, clozapine, oxcarbazepine, tamoxifen, cariprazine a
(not yet commercially available)
Combination therapy: lithium or divalproex + haloperidol, lithium + carbamazepine, adjunctive tamoxifen

Not recommended

Monotherapy: gabapentin, topiramate, lamotrigine, verapamil, tiagabine
Combination therapy: risperidone + carbamazepine, olanzapine + carbamazepine

ECT = electroconvulsive therapy; XR or ER = extended release.
a
New or change to recommendation.
b
Given the metabolic side effects, use should be carefully monitored.

well established (level 1) (1–3). Two large, 12-week,
open, randomized trials comparing lithium to
divalproex found comparable eﬃcacy and
tolerability of these agents for the treatment of
acute mania (46, 47).
A large (n = 521), 12-week RCT compared
divalproex, olanzapine, and placebo in patients
with mild to moderate mania. At three weeks,
improvements in mania scores were signiﬁcant with
olanzapine versus placebo but not with divalproex
versus olanzapine or placebo. After 12 weeks of
treatment, improvements in both active treatment
groups were signiﬁcant versus placebo, but olanzapine was signiﬁcantly more eﬃcacious than
divalproex (48).

The results of two three-week RCTs assessing
the eﬃcacy of the ER formulation of divalproex
for the treatment of acute mania have now been
published (49, 50) One study demonstrated
statistically signiﬁcant improvements in manic
symptoms compared to placebo (level 2) (49),
while the other did not (50). In the ﬁrst, Bowden
et al. (49) found signiﬁcantly greater improvement in manic symptoms and higher response
rates (48% versus 34%, p = 0.012) with divalproex ER versus placebo, while Hirschfeld et al.
(50) found no statistically signiﬁcant diﬀerence in
mania scores with divalproex ER versus placebo;
however, discontinuation rates were over 80%
and dosing may have been lower than optimal.
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Given the level 1 evidence to support the immediate-release formulation of divalproex, as well as
the high discontinuation rate and dosing issues in
the negative trial, divalproex ER has been added
as a ﬁrst-line therapy, although, if prescribed,
attention should be paid to dosing and serum
levels.
Atypical antipsychotic monotherapy. Substantial
RCT data support the eﬃcacy of atypical antipsychotic monotherapy with olanzapine, risperidone, quetiapine, ziprasidone, and aripiprazole
for the ﬁrst-line treatment of acute mania (level 1)
(1–3).
As reviewed earlier, a large (n = 521), 12-week
RCT comparing divalproex, olanzapine, and
placebo in patients with mild to moderate mania
found that improvements in mania scores with olanzapine were signiﬁcantly greater than with placebo after three weeks, and greater than with both
divalproex and placebo after 12 weeks (48).
In a meta-analysis of six aripiprazole monotherapy RCTs in acute mania involving 2303 patients,
the eﬀect size was 0.34 versus placebo at week
three, with a response generally being seen at day
three (level 1) (51). A 12-week RCT of aripiprazole
monotherapy in acute mania found signiﬁcantly
greater improvements in the Young Mania Rating
Scale (YMRS) scores at week three with aripiprazole ()12.0, p < 0.05) or haloperidol ()12.8,
p < 0.01) compared to placebo ()9.7), which were
maintained to week 12; haloperidol was included
as an active control and was not statistically
compared to aripiprazole (52).
Additional data are also available comparing
ziprasidone to placebo and haloperidol in a
12-week RCT. Improvements in mania scores and
response rates at week three were signiﬁcantly
greater than with placebo for both active treatments, but haloperidol was signiﬁcantly more
eﬀective than ziprasidone. During the nine-week
extension phase, responses were maintained for the
majority of patients receiving active treatments.
Ziprasidone showed a superior tolerability proﬁle
and lower discontinuation rates during the extension phase (53).
Two three-week, double-blind RCTs demonstrating the eﬃcacy of paliperidone ER in patients
with manic or mixed episodes, which were previously cited in abstract form, have now been
published (level 1) (54, 55). Paliperidone ER has
been upgraded to a ﬁrst-line option.
Two three-week, double-blind RCTs demonstrating the eﬃcacy of asenapine as monotherapy
for acute mania (56, 57), as well as nine-week and
40-week extension phase results demonstrating the
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maintenance of beneﬁts (58, 59), which were
previously cited in abstract form, have now been
published (level 1). Asenapine has been upgraded
to a ﬁrst-line option.
Atypical antipsychotic combination therapy. As
previously reported, a six-week, placebo-controlled
RCT showed that adding aripiprazole to lithium or
divalproex in 384 patients with an inadequate
response was signiﬁcantly more eﬀective than
placebo from week 1 onward (60). A 46-week
open-label extension of this study found that
aripiprazole as an adjunct to lithium or divalproex
provided continued improvement in mania but not
depression (61).
A 12-week RCT demonstrating signiﬁcant
improvements in mania symptoms with adjunctive
asenapine added to lithium ⁄ divalproex compared
to placebo that was previously cited in abstract
form has still not been published, but 40-week
extension results have now been reported (level 2)
(62). Of the original 318 patients, 71 completed the
40-week extension; there were additional improvements in mania scores at 52 weeks in both the
asenapine and placebo groups. Adjunctive asenapine has been moved to a ﬁrst-line option.
Step 3. Add-on or switch therapy (alternate ﬁrst-line
therapies): No changes from 2005 guidelines.
Step 4. Add-on or switch therapy (second- and thirdline therapies):
Second-line options. A small RCT in 44 patients
with manic, mixed, or depressive episodes found
that among patients who were on, or thought to
beneﬁt from, carbamazepine, there were no diﬀerences in mood ratings or in the total level of
adverse events with immediate-release versus ER
carbamazepine (63, 64). However, there were
signiﬁcantly fewer autonomic and gastrointestinal
adverse events with carbamazepine ER (64).
While electroconvulsive therapy (ECT) can be
an eﬀective option, research studies have not been
rigorous and therefore it continues to be recommended as a second-line therapy (level 3) (1). In
an RCT of ECT as adjunct to antipsychotic
therapy, bilateral, twice-weekly ECT delivered at
stimulus intensities just above seizure threshold
was as eﬀective and safe as ECT administered
at stimulus intensities 2.5 times the seizure
threshold in rapidly resolving the symptoms of
acute mania (65).
In a meta-analysis of 13 haloperidol-controlled
trials, the drug was signiﬁcantly more eﬀective than
lithium, divalproex, quetiapine, aripiprazole,
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ziprasidone, carbamazepine, asenapine, and lamotrigine (43). Given the strong data for eﬃcacy,
haloperidol has been upgraded to a second-line
option. However, haloperidol should only be used
on a short-term basis to treat acute mania as
continuation of haloperidol may increase the risk
of a depressive episode (43).
Third-line options. A small (n = 60), 12-week RCT
comparing oxcarbazepine to divalproex in patients
with acute mania found no signiﬁcant diﬀerences
in improvements in mania scores or remission rates
between the two treatments, but divalproex was
associated with more adverse events (66). In
another small (n = 52) RCT, adjunctive oxcarbazepine was more eﬀective than carbamazepine as add-on therapy in patients who had
previously been inadequate responders to lithium,
although both agents improved manic and depressive scores versus baseline (67). As described in the
previous updates to these guidelines, there are
other small positive trials, but there is also a
negative placebo-controlled RCT, and these new
trials are small and do not include a placebo
control arm; therefore, oxcarbazepine remains as a
third-line option.
Cariprazine, a new dopamine D3 ⁄ D2 receptor
antagonist, appears promising for the treatment of
acute mania, but has not yet been approved by
Canadian or US regulatory agencies. The results
of a three-week, phase 2, RCT, presented in
abstract form, reported signiﬁcant reductions in
mania scores with cariprazine compared to placebo
(level 2) (68).
Step 5. Add-on novel or experimental agents:
Zotepine is an antipsychotic agent that has been
approved in some European countries and in
Japan for the treatment of schizophrenia. In a
four-week, single-blind trial, adjunctive zotepine
added to lithium or divalproex therapy in 45
inpatients with moderate-to-severe mania was as
eﬀective as adjunctive haloperidol in improving
mania scores (69).
Two RCTs have now demonstrated the eﬃcacy
of adjunctive allopurinol for the treatment of acute
mania (level 1) (70, 71). In an eight-week RCT,
allopurinol as adjunct to lithium plus haloperidol
was found to be signiﬁcantly more eﬀective than
placebo in 82 patients hospitalized with acute
mania (70). In the second RCT (n = 180), comparing the addition of allopurinol, dipyridamole,
or placebo to lithium for four weeks, allopurinol
led to signiﬁcantly greater improvements in mania
scores and remission rates versus placebo (71).
Although there is level 1 evidence for the use of

allopurinol, given that it can cause hepatomegaly
as well as hypersensitivity reactions such as
Steven–Johnson syndrome and toxic epidermal
necrolysis, it is recommended only for those
patients that are refractory to other ﬁrst-, second,
and third-line treatments.
Preliminary evidence previously suggested
antimanic eﬃcacy associated with tamoxifen (1).
A six-week, placebo-controlled RCT has now
demonstrated signiﬁcantly greater improvements
in mania scores with tamoxifen as an adjunct to
lithium in 40 inpatients with acute mania compared to lithium alone (level 2) (72).
In a three-week RCT in 88 acutely manic
patients on divalproex, adjunctive folic acid was
signiﬁcantly better than placebo in improving
mania scores (level 2) (73).
A three-week, open-label, pilot trial in 33 patients
with manic or mixed episode BD I found that 30–
50% of patients responded to doses of memantine
ranging from 20 mg to 40 mg (level 3) (74).
Given the limited data, at this time, these agents
can only be recommended as add-on therapies
after failure of standard therapies.
Adjunctive therapies with negative data requiring
further study: A six-week RCT that found no
signiﬁcant improvements in manic symptoms with
adjunctive ﬂexible-dose paliperidone in patients
with manic or mixed episodes who had not
responded to lithium or divalproex, was previously
cited in abstract form and has now been published
(level 2, negative) (75). Given that paliperidone
monotherapy is eﬀective, and that lithium or
valproate does not aﬀect the metabolism of paliperidone, the lack of eﬃcacy of combination
therapy is surprising. In spite of the fact that it
was a ﬂexible-dose trial, paliperidone ER may have
been under-dosed, since the monotherapy studies
suggest that 12 mg ⁄ day is the most eﬀective dose
and the mean dose used was 8.1 (3.30) mg ⁄ day,
with 45% of the patients receiving a ﬁnal dose of
6 mg ⁄ day in this trial. In addition, a post-hoc
subgroup analysis found that adjunctive paliperidone ER was superior to lithium or divalproex
monotherapy for patients diagnosed with a manic
episode (p = 0.020).
A three-week RCT in over 600 patients with BD
mania ⁄ mixed episodes found no signiﬁcant
beneﬁts with adjunctive ziprasidone at either high
(120–160 mg ⁄ day) or low (40–80 mg ⁄ day) doses
compared to placebo (76). The trial has not yet
been published, but the results are available at
http://www.clinicaltrials.gov.
In light of these negative trials, adjunctive use of
paliperidone ER or ziprasidone, at the dosages

7

Yatham et al.

used by the above-noted studies, is not recommended.
Mania with psychotic features

A meta-analysis of four RCTs of aripiprazole
supports its antipsychotic eﬀects, as measured
by the Positive and Negative Syndrome Scale
(PANSS) score, during the acute manic and
maintenance phases of BD (77). The eﬀect sizes
for aripiprazole versus placebo were highest for the
PANSS–positive subscale (0.28) and the PANSS–
hostility subscale (0.24).
Mixed states

A six-week RCT (n = 202) evaluating adjunctive
olanzapine compared to adjunctive placebo demonstrated signiﬁcantly greater and earlier reductions in manic and depressive symptoms in patients
with mixed episodes inadequately controlled with
divalproex (78). Post-hoc analysis of this study
found that response (Clinical Global Impression–
Severity decrease ‡ 1) at day two was predictive of
mixed symptom remission (79).
A post-hoc analysis of two asenapine RCTs in
patients with manic or mixed episodes demonstrated statistically signiﬁcant decreases in depresStep 1
Review general
principles
&
assess medication
status

sion scores with asenapine versus placebo in
patients with severe baseline depressive symptoms
(n = 604); diﬀerences between the active comparator olanzapine and placebo were not signiﬁcant,
which makes the interpretation of these results
more diﬃcult as it raises the possibility of a
negative study (80).
Section 4. Acute management of bipolar depression

Pharmacological treatment of depressive episodes

Pharmacological management of acute bipolar
depressive episodes should follow the algorithm
outlined in Figure 4.1 (1–3). The recommendations
for ﬁrst- and second-line therapies are largely
unchanged, except for the addition of lurasidone
monotherapy and lurasidone or lamotrigine plus
lithium or divalproex as second-line options. Based
on negative data, ziprasidone alone or as adjunctive therapy, and adjunctive levetiracetam have
been added as not-recommended options for the
treatment of bipolar depression (Table 4.3).
Several meta-analyses have assessed the eﬃcacy
of atypical antipsychotic agents and other medications for the treatment of bipolar depression
(81, 82). A meta-analysis of atypical antipsychotic
agents for bipolar depression included ﬁve trials
(two monotherapy trials with each of quetiapine

Assess safety/functioning
Behavioural strategies/rhythms
Psychoeducation
On DVP

On OLZ, RIS,
ARI, or ZIP

Add SSRIa/BUP
or add/switch to
Li , LAM or
QUE

Add SSRIa, Li
or LAM
or switch to Li,
LAM or QUE

On first-line
agent

Not on
medication

+
Step 2
Initiate/optimize,
check compliance

LAM

Li

QUE

OLZ
+SSRIa

Li or DVP
+SSRIa/ BUP

Li + DVP

No
response
Step 3
Add-on or
switch therapy

Add/switch
to Li
or QUE

Add
SSRIa/BUP or
add/switch to
LAM or QUE

Add SSRI, Li or
LAM or switch
to Li, LAM or
OLZ + SSRI a

Switch to QUE,
Li,
QUE+SSRIa, Li
Li + SSRIa/BUP
b
or LAM

No
response
Step 4
Add-on or
switch therapy
No
response
Step 5
Add-on or
switch therapy

Switch Li or
DVP to QUE or
OLZ or switch
SSRIa/BUP to
LAMc

Add
SSRIa/BUP
or switch
Li or DVP to
LAM or QUE

Replace one or both agents with
alternate first- or second-line agents

Consider ECT, third-line agents and novel or
experimental options

Fig. 4.1. Treatment algorithm for the management of bipolar I depression. Novel ⁄ experimental agents: adjunctive pramipexole,
eicosapentaenoic acid (EPA), riluzole, topiramate, N-acetyl cysteine (NAC), ketamine, armodaﬁnil, and chronotherapy.
DVP = divalproex; OLZ = olanzapine; RIS = risperidone; ARI = aripiprazole; ZIP = ziprasidone; SSRI = selective serotonin
reuptake inhibitor; BUP = bupropion; Li = lithium; LAM = lamotrigine; QUE = quetiapine; ECT = electroconvulsive therapy.
a
Except paroxetine. bOr switch the SSRI to another SSRI. cOr switch the SSRI or BUP to another SSRI or BUP.
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Table 4.3. Recommendations for pharmacological treatment of acute bipolar I depressiona
First line

Monotherapy: lithium, lamotrigine, quetiapine, quetiapine XR
Combination therapy: lithium or divalproex + SSRIb, olanzapine + SSRIb, lithium + divalproex, lithium or
divalproex + bupropion

Second line

Monotherapy: divalproex, lurasidonec
Combination therapy: quetiapine + SSRIb, adjunctive modafinil, lithium or divalproex + lamotriginec, lithium
or divalproex + lurasidonec

Third line

Monotherapy: carbamazepine, olanzapine, ECT d
Combination therapy: lithium + carbamazepine, lithium + pramipexole, lithium or divalproex + venlafaxine,
lithium + MAOI, lithium or divalproex or AAP + TCA, lithium or divalproex or carbamazepine + SSRIb +
lamotrigine, quetiapine + lamotriginec

Not recommended

Monotherapy: gabapentin, aripiprazole, ziprasidone c
Combination therapy: adjunctive ziprasidonec, adjunctive levetiracetamc

AAP = atypical antipsychotic agent; ECT = electroconvulsive therapy; MAOI = monoamine oxidase inhibitor; TCA = tricyclic antidepressant; SSRI = selective serotonin reuptake inhibitor; XR = extended release.
a
The management of a bipolar depressive episode with antidepressants remains complex. The clinician must balance the desired effect
of remission with the undesired effect of switching. See detailed discussion in Clinical questions and controversies section.
b
Except paroxetine.
c
New or change to recommendation.
d
Could be used as first- or second-line treatment in certain situations (see text).

and aripiprazole, and one combination trial with
olanzapine) and found signiﬁcantly greater
improvement compared to placebo for weeks 1–6
but not for weeks seven and eight (primarily
accounted for by a tapering of eﬀect in aripiprazole
studies) (81). This suggests that the eﬃcacy of these
agents is not a class eﬀect and that individual
agents may show diﬀerential beneﬁts, and, as such,
generalizations on the role of atypical antipsychotic agents for depressive symptoms cannot be
made. Another meta-analysis included 19 trials
assessing mainly quetiapine (ﬁve trials) and lamotrigine (six trials), but also paroxetine, lithium,
olanzapine, aripiprazole, phenelzine, and divalproex for the treatment of bipolar depression (82).
This analysis found the highest reductions in
Montgomery–Åsberg Depression Rating Scale
(MADRS) scores with the olanzapine plus ﬂuoxetine combination and quetiapine monotherapy
compared to placebo. In this analysis, lamotrigine,
paroxetine, aripiprazole, and lithium were not
signiﬁcantly diﬀerent from placebo in improving
depression scores. However, as cited in previous
iterations, a meta-analysis of individual patient
data supported the eﬃcacy of lamotrigine monotherapy (83).
Step 1. Review general principles and assess medication status: Recommendations from 2005 guidelines remain unchanged.
Step 2. Initiate or optimize therapy and check
adherence (ﬁrst-line therapies): Lithium, lamotrigine,
quetiapine, and quetiapine extended release (XR)

monotherapies, as well as lithium or divalproex
plus selective serotonin reuptake inhibitor (SSRI),
olanzapine plus SSRI, lithium plus divalproex, and
lithium or divalproex plus bupropion all continue
to be recommended as ﬁrst-line choices for bipolar
depression.
Data suggest that the absence of early improvement (2–3 weeks) may be a highly reliable predictor of eventual non-response, suggesting that these
patients may beneﬁt from a change in therapy
(84, 85).
Lithium. The early results of the National Institute of Mental Health (NIMH) lithium treatment
moderate dose use study have been presented
(86). This pragmatic study randomized 283
patients with BD I or BD II to receive six
months
of
open-label
Ômoderate
doseÕ
(600 mg ⁄ day) lithium plus optimized treatment
[per Texas Medication Algorithms (87)] versus
optimized treatment alone and found no significant diﬀerences between treatment groups. However, given that this was an open-label study, and
in the absence of further study details, recommendations for adjunctive lithium use remain
unchanged.
Quetiapine monotherapy. The four large published
RCTs demonstrating the eﬃcacy of quetiapine
monotherapy in bipolar depression, which were
cited in previous iterations of these guidelines, have
now all been published: BipOLar DEpRession
(BOLDER) I (88) and II (89) and Eﬃcacy of
Monotherapy SEROQUEL in BipOLar DEpres-
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sioN (EMBOLDEN) I (90) and EMBOLDEN II
(91) (level 1).
The eight-week RCT demonstrating signiﬁcantly
greater improvement in depressive symptoms with
quetiapine XR monotherapy in patients with BD I
or BD II depression, which was previously cited,
has now been published (92).
Olanzapine + ﬂuoxetine. There are level 1 data
demonstrating the eﬃcacy of olanzapine–ﬂuoxetine combination (OFC) therapy for the treatment
of BD I depression (1–3). Follow-up results from a
previously described RCT [seven-week outcome
data (93)] found signiﬁcantly greater improvements
in depressive and manic symptoms with OFC
versus lamotrigine in 410 patients with BD I at
study end (94). However, OFC treatment was
associated with a signiﬁcantly increased risk of
treatment-emergent hypercholesterolemia and
weight gain. In addition, a post-hoc analysis of a
previously cited combination study (95) found that
both OFC and olanzapine monotherapy were more
eﬃcacious than placebo in patients with BD I
mixed depression (i.e., syndromal depression and
subsyndromal mania ⁄ hypomania).

cacy, lurasidone will be upgraded to one of the
ﬁrst-line treatments in the next revision.
Lamotrigine + lithium or divalproex. In an eightweek RCT, the acute eﬀect of lamotrigine was greater
than that of placebo as an add-on to lithium for BD I
or BD II depression (n = 124) (100). Non-responders in this trial entered a second phase in which
paroxetine was added; this addition showed beneﬁt in
non-responders to lithium + placebo, but not in
non-responders to lithium + lamotrigine (101).
Given the slow titration required for lamotrigine,
this treatment is recommended either in monotherapy or as an add-on therapy primarily for those with
mild-to-moderate bipolar depression, and in particular for those with depression recurrences, given its
eﬃcacy in preventing depressive relapses.
Step 4. Add-on or switch therapy (alternate ﬁrst- or
second-line therapies): No changes from 2005
guideline (1).
Step 5. Add-on or switch therapy (third-line agents
and novel ⁄ experimental therapies):
Third-line options

Step 3. Add-on or switch therapy (alternate ﬁrst- or
second-line therapies):
Second-line options
Divalproex monotherapy. Four small RCTs have
assessed the eﬃcacy of divalproex or divalproex ER
for the treatment of BD I or BD II depression (level
1) (96, 97). Two meta-analyses of these trials (total
n = 142), by separate groups, concluded that
divalproex was more eﬀective than placebo for the
treatment of bipolar depression, but the strength of
the conclusions was limited by sample size (96, 97).
Therefore, given the limited evidence, divalproex
continues to be recommended as a second-line option.
Lurasidone. Two six-week RCTs have demonstrated the eﬃcacy of lurasidone as monotherapy
(98) or as an adjunct (99) in patients with bipolar
depression. Lurasidone monotherapy signiﬁcantly
reduced depressive symptoms in patients with BD I
depression as early as week two compared to
placebo (level 2) (98). Similarly, when used as an
adjunct to lithium or divalproex, lurasidone
signiﬁcantly reduced depressive symptoms, and
improved functioning and quality of life compared
to placebo in patients with BD I depression who
had an inadequate response to lithium or divalproex alone (level 2) (99). These data look very
promising and if clinical experience supports eﬃ-
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Olanzapine monotherapy. There are now two large
RCTs demonstrating the eﬃcacy of olanzapine
monotherapy for the treatment of bipolar depression (level 1) (95, 102). In the earlier of these two
trials, olanzapine monotherapy demonstrated
a statistically signiﬁcant, but clinically modest
antidepressant eﬀect in a large (n = 833), eightweek RCT in patients with bipolar depression (95),
and was recommended as a third-line option (1).
In the subsequent large RCT, available in
abstract form, 514 patients with bipolar depression achieved signiﬁcantly greater improvement in
depressive symptoms with olanzapine compared
to placebo (MADRS )13.8 versus )11.7, p =
0.018) over six weeks of treatment (102). However, olanzapine was also associated with significantly greater rates of metabolic changes (102). A
small (n = 20), open-label study provided additional support for the eﬃcacy of olanzapine
monotherapy in patients with BD I or BD II
depression (103).
Although there is level 1 evidence, the magnitude
of beneﬁt of olanzapine monotherapy was only
modestly greater than that of placebo (95, 102). In
the earlier trial (95), the increased eﬃcacy of
olanzapine relative to placebo was mainly
accounted for by changes in sleep, appetite, and
inner tension, which are not the core symptoms of
depression (81). In addition, as adverse events were
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marked in the recent trial (102), this strategy
continues to be recommended as a third-line
option.
Quetiapine + lamotrigine. A small, open trial in 39
patients with BD I and BD II found that the
combination of lamotrigine plus quetiapine was
beneﬁcial in treatment-resistant bipolar depression
(level 3) (104).
Carbamazepine. There is additional evidence to
support the use of carbamazepine (level 2), as a small
RCT in a mixed population of 44 patients with BD
found that ER carbamazepine was as eﬀective as the
immediate-release form, with fewer autonomic and
gastrointestinal adverse events (63, 64).
ECT. As stated in previous iterations of the guidelines, the use of ECT should be considered earlier in
patients who have psychotic bipolar depression, in
those at high risk for suicide, and in those with
signiﬁcant medical complications due to not drinking and eating. Clinical experience and open-label
data continue to accumulate and support the eﬃcacy
of ECT. In an open trial, similar rates of response
and remission were observed in patients with bipolar
depression (70% and 26%, respectively) and those
with mixed states (66% and 30%, respectively)
(105). A retrospective analysis of 201 patients with
BD receiving ECT concluded that those receiving
concomitant anticonvulsants achieved comparable
symptomatic improvement to those not on anticonvulsants; however, they required a signiﬁcantly
greater number of ECT sessions to achieve this
(106). Two RCTs comparing diﬀerent ECT protocols found no diﬀerence in response rates in patients
with bipolar or unipolar depression (107, 108).
Novel or experimental agents

Data were previously described demonstrating the
beneﬁts of adjunctive use of the following agents:
pramipexole (level 2), eicosapentaenoic acid (EPA)
(level 2), riluzole (level 3), topiramate (level 3), and
N-acetyl cysteine (NAC) (level 2) (1–3).
Additional open-label data support the use of
adjunctive riluzole and adjunctive NAC (109, 110).
Patients in a small, open-label, imaging study
reported improvements in depressive symptoms
with riluzole (level 3) (109), while data from a large
(n = 149), eight-week, open-label trial found
signiﬁcant improvement in depressive symptoms
with adjunctive NAC in patients with BD I, II, or
NOS depression (110).
Preliminary data are also available to support
other novel treatments not previously investigated

in patients with bipolar depression, including
adjunctive ketamine, armodaﬁnil, and chronotherapy. A two-week, crossover RCT assessing adjunctive ketamine infusion in patients with treatmentresistant bipolar depression identiﬁed a robust early
antidepressant eﬀect (within 40 min), with improvement remaining signiﬁcant versus placebo through
day three (level 2) (111). An eight-week RCT in 257
patients with BD I depression reported a trend
toward greater improvement in depressive symptoms with adjunctive armodaﬁnil versus placebo on
some, but not all depression symptom scales (level 2)
(112). Adjunctive combined chronotherapy (sleep
deprivation, exposure to bright light, and sleepphase advance) demonstrated a more rapid and
sustained antidepressant response compared to
medication alone (lithium + antidepressant) in a
seven-week RCT in 49 patients with bipolar depression (level 3) (113). Patients receiving adjunctive
chronotherapy experienced a signiﬁcantly greater
reduction in depressive symptoms within 48 hours,
which was sustained throughout the seven weeks.
Not recommended for the treatment of acute bipolar
depression:
Ziprasidone monotherapy. Data are now available
from two negative RCTs of ziprasidone monotherapy in BD I depression (level 1, negative) (114,
115). The trials have not yet been published, but
results are available at http://www.clinicaltrials.gov
(114, 115). Both were large trials (n = 381 and
n = 504, respectively) in patients with BD I
depression, and both demonstrated no signiﬁcant
improvements in depression scores compared to
placebo. While ziprasidone is not recommended
for bipolar depression, patients who are using
ziprasidone with beneﬁt (initiated during mania)
do not need to have it discontinued.
Adjunctive therapies with negative data requiring
further study:
Adjunctive ziprasidone. A large RCT assessing
adjunctive ziprasidone (mean dose 90 mg) added
to therapy with lithium, divalproex, or lamotrigine
in 298 patients with BD I depression found no
signiﬁcant diﬀerence between active treatment and
placebo (level 2, negative) (116).
Adjunctive aripiprazole. While open-label trials
suggest a beneﬁt of adjunctive aripiprazole for
the treatment of bipolar depression (level 3) (117,
118), a small RCT did not ﬁnd a signiﬁcant eﬀect
compared to placebo (level 2, negative) (119). In a
six-week RCT, 23 inpatients with bipolar depres-
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sion on lithium or divalproex were given open-label
citalopram, and randomized to adjunctive aripiprazole or placebo. Depressive symptoms improved,
with no signiﬁcant diﬀerences between treatment
groups (level 2 negative) (119).
In a 16-week, prospective, open-label trial,
aripiprazole (add-on or monotherapy) was associated with a signiﬁcant decline in depressive symptoms over 16 weeks among 85 patients with bipolar
depression who were unresponsive to other medications (lithium, anticonvulsants, or antipsychotic
agents) (level 3) (117). There was also a signiﬁcant
reduction in self-rated anhedonia among patients
with BD I depression treated with aripiprazole
in the same study (120). Another small (n = 20),
six-week, open-label trial demonstrated improvement in depressive symptoms, with a 44% response
rate with aripiprazole as add-on or monotherapy
for BD I, II, or NOS depression (level 3) (118).
Adjunctive levetiracetam. A six-week RCT in 32
patients with bipolar depression found no signiﬁcant diﬀerences in the change in depression scores
with adjunctive levetiracetam versus placebo (level
2, negative) (121).
Clinical questions and controversies

What is the role of antidepressants in patients with
bipolar depression?
The role of antidepressants in patients with
bipolar depression remains one of the most controversial areas in psychiatry. Antidepressants are
the most commonly used treatments for bipolar
depression (122, 123) as clinicians continue to
believe that, based on their clinical experience,
these are eﬀective for bipolar depression. However,
the limited, but growing body of clinical trial data
has not been consistent in supporting their role.
For instance, OFC was shown to be more eﬀective
than placebo or olanzapine monotherapy (93, 95),
but the combination of paroxetine or bupropion
with a mood stabilizer was not more eﬀective than a
mood stabilizer plus placebo (124). However, this
study had severe methodological limitations; most
patients were also participating in a psychotherapy
trial, and an unknown proportion of patients
continued to use the previous antidepressant they
had been on at baseline. In another study, paroxetine monotherapy (20 mg ⁄ day) was not superior to
placebo in improving bipolar depressive symptoms
(125). It is unknown if higher doses of paroxetine
would have been more eﬀective.
Although individual studies are contradictory,
the most recent meta-analysis, which included 15

12

RCTs (126), found a strong trend for superiority of
antidepressants over placebo for the acute treatment
of bipolar depression (p = 0.06). Antidepressants
were not associated with a signiﬁcantly increased
risk of manic switch (126). Most negative studies of
antidepressants for bipolar depression to date have
employed paroxetine as the antidepressant (91, 125,
127). A meta-analysis of the eﬃcacy of antidepressants in unipolar depression (128) suggested that
clinically important diﬀerences exist between various antidepressants in terms of eﬃcacy and acceptability. Interestingly, paroxetine was inferior to a
number of other antidepressants in this meta-analysis. The risk of manic ⁄ hypomanic switch does not
appear to be a major concern with modern antidepressants when used in conjunction with a Ômood
stabilizerÕ or an atypical antipsychotic agent, at least
during short-term treatment; therefore, safety does
not appear to be a signiﬁcant issue during the acute
treatment of bipolar depression. An important
caveat is that the current deﬁnition of switch
requires threshold mania; milder switches, which
are common, are not captured by the default
deﬁnition (129). Similarly, the metrics of cycle
acceleration are not captured in current deﬁnitions
or trial designs (130).
Given the above, we believe that the following
conclusions and recommendations are warranted
regarding the use of antidepressants for bipolar
depression: (i) SSRIs (other than paroxetine) and
bupropion could be used as ﬁrst-line treatments in
conjunction with a mood stabilizer for acute shortterm treatment of bipolar depression, with the
objective of tapering and discontinuing antidepressants 6–8 weeks after full remission of depression;
(ii) avoid the use of tricyclic antidepressants and
venlafaxine (131, 132) as they are associated with
an increased risk of manic switch; (iii) antidepressants should not be used to treat a current mixed
episode or in patients with a history of rapid
cycling; (iv) monotherapy with antidepressants is
not recommended for bipolar depression.
Section 5. Maintenance therapy for bipolar disorder

Adherence

New data provide further insight into adherence to
maintenance therapy in patients with BD. In
several analyses, adherence was positively associated with higher satisfaction with medication,
monotherapy, a college degree, and fear of relapse,
and was negatively associated with illness factors
(substance use, previous hospitalization, psychotic
symptoms, reduced insight into illness), medication
factors (side eﬀects, no perceived daily beneﬁt,
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diﬃculties with medication routines), and patient
attitudes (belief that medications are unnecessary,
negative attitudes toward medications, perceived
change in appearance, perceived interference with
life goals) (133–139). Under-dosing can also lead to
higher discontinuation rates; patients receiving
lower doses of ziprasidone had signiﬁcantly higher
discontinuation rates than those receiving medium
or high doses (140).
Non-adherence has been linked to a high
frequency of episodes (particularly depressive
episodes), a higher risk of hospitalization and
emergency room visits, as well as higher employee
costs of absenteeism, short-term disability, and
workersÕ compensation (137, 141–144). In an
analysis involving UK data, the direct costs of
care were two to three times higher in patients who
relapsed compared to those who did not over the
6–12-month follow-up (145).
Predictors of recurrence

In observational studies, predictors of symptomatic remission and recovery during 1–2 years of
follow-up in patients with manic episodes included:
Caucasian ethnicity, a previous manic episode,
good social functioning (no work or social impairment, living independently or with family), outpatient treatment, and being neither satisﬁed nor
dissatisﬁed with life (146, 147).
In patients with rapid cycling treated with lithium
or divalproex, increased risk for non-stabilization
was associated with a history of recent substance use
disorder (SUD), early-life verbal abuse, female
gender, and late onset of ﬁrst depressive episode
(148). Among responders to long-term lithium
therapy, the risk of recurrence was higher in those
with atypical features (mainly mood-incongruent
psychotic symptoms), inter-episodic residual symptomatology, and rapid cycling (149).
Psychosocial interventions for maintenance therapy

As reported in previous iterations of these guidelines, data have supported the beneﬁts of adjunctive psychoeducation, CBT, family therapy, and
IPSRT in reducing recurrences and improving
symptoms in patients with BD (1–3). However,
recent meta-analyses assessing the eﬃcacy of psychotherapies for patients with BD have reached
discordant conclusions. One meta-analysis of four
RCTs concluded that CBT had a small eﬀect size
for depressive symptoms compared to treatment as
usual or wait-list controls (150). A second analysis
included 12 trials and found low to medium eﬀect
sizes associated with adjunctive CBT at the end of

treatment and at follow-up (151). Another
meta-analysis concluded that CBT was likely not
an eﬀective treatment strategy for the prevention of
relapse in BD (152).
Given the transient beneﬁt of CBT in the ﬁrst
major study of this strategy in patients with BD (153)
and the negative results of a large RCT (154), the
true beneﬁt of CBT is unclear, beyond its common
core element of psychoeducation (155). However,
two new RCTs provide some promise. In one study
comparing a group CBT intervention to treatment
as usual in 50 patients, group CBT was associated
with a longer median time to relapse, but no
diﬀerences in time to recurrence or number of
episodes (156). In a 14-week study comparing the
CBT (n = 27) and control pharmacotherapy
(n = 14) groups, there was a slight, although nonsigniﬁcant, reduction in depressive symptoms in the
CBT group (157). Both of these small studies
demonstrated the feasibility of group CBT rather
than its eﬃcacy, and proper replication is needed. In
addition, a previously reported RCT (n = 204)
(22), which has now been published, compared six
sessions of group psychoeducation to 20 sessions of
individual CBT. Both treatments demonstrated a
signiﬁcant beneﬁt in terms of mood stability and
reduction of recurrence, but there were no diﬀerences between the two treatments. Since the
psychoeducation treatment was designed to be
delivered by psychiatric nurses and was documented to be much less expensive than individual
CBT, the study suggested that group psychoeducation should be prioritized as a ﬁrst universal
psychosocial treatment for BD.
RCTs of adjunctive group psychoeducation
programs demonstrated a longer time to recurrence, fewer recurrences of any type, less time
acutely ill, and fewer days of hospitalization during
1–5 years of follow-up (158, 159). A 12-week
dyadic (patient–companion) group-based psychoeducation program demonstrated signiﬁcantly lower relapse rates and a longer time to relapse
compared to treatment as usual during a 60-week
follow-up (160).
Pharmacological treatments for maintenance therapy

As discussed in previous guideline iterations, almost
all modern maintenance studies have used an
enriched design. The only exceptions are some of
the older maintenance studies with lithium, which
showed the eﬃcacy of lithium for maintenance
treatment in non-enriched samples. Given the eﬃcacy of various treatments with enriched design
studies, it makes intuitive sense that, in general, the
treatment that worked during the acute phase is
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Table 5.5. Recommendations for maintenance pharmacotherapy of bipolar disorder
First line

Monotherapy: lithium, lamotrigine (limited efficacy in preventing mania), divalproex, olanzapinea,
quetiapine, risperidone LAIb, aripiprazoleb
Adjunctive therapy with lithium or divalproex: quetiapine, risperidone LAIb, aripiprazoleb, ziprasidoneb

Second line

Monotherapy: carbamazepine, palideridone ERc
Combination therapy: lithium + divalproex, lithium + carbamazepine, lithium or divalproex + olanzapine,
lithium + risperidone, lithium + lamotrigine, olanzapine + fluoxetine

Third line

Monotherapy: asenapinec
Adjunctive therapy: phenytoin, clozapine, ECT, topiramate, omega-3-fatty acids, oxcarbazepine,
gabapentin, asenapinec

Not recommended

Monotherapy: gabapentin, topiramate, or antidepressants
Adjunctive therapy: flupenthixol

LAI = long-acting injection; ER = extended release; ECT = electroconvulsive therapy.
a
Given the metabolic side effects, use should be carefully monitored.
b
Mainly for the prevention of mania.
c
New or change to recommendation.

likely to be eﬀective in the maintenance phase [please
see the original 2005 guidelines: Section 5. Maintenance therapy for bipolar disorder: General principles
(1)]. Based on new evidence, asenapine alone and as
adjunctive therapy have been added as third-line
options (Table 5.5) (1–3).
First-line options: Lithium, divalproex, olanzapine,
and quetiapine (for both depression and mania), as
well as lamotrigine (primarily for preventing depression), risperidone long-acting injection (LAI) and
ziprasidone (primarily for preventing mania) continue to be ﬁrst-line monotherapy options for
maintenance treatment of BD (1–3). Quetiapine,
risperidone LAI (mania), aripiprazole (mania), and
ziprasidone (mania) are also recommended as
adjunctive therapy with lithium or divalproex.
A systematic review of pharmacological interventions for the prevention of relapse in BD
included 34 RCTs and quasi-RCTs, and concluded
that lithium, olanzapine, and aripiprazole had
signiﬁcant eﬀects in the prevention of manic
relapses, as did divalproex, lamotrigine, and imipramine in the prevention of depressive symptoms
(161). A meta-analysis of 20 RCTs (n = 5364)
assessing the relative risk for relapse in patients
with BD in remission conﬁrmed the eﬃcacy of
lithium, divalproex, lamotrigine, and a number of
atypical antipsychotic agents in preventing relapse
to any episode versus placebo (162).
Lithium ⁄ divalproex. The Bipolar Aﬀective disorder
Lithium ⁄ ANti-Convulsant Evaluation (BALANCE) study randomized 330 patients with BD
to open-label lithium monotherapy, divalproex
monotherapy, or the combination after an active
run-in period on the combination (163). Both the
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combination and lithium monotherapy were
signiﬁcantly more eﬀective than divalproex monotherapy in preventing relapse during up to two
years of follow-up. Combination therapy was not
signiﬁcantly more eﬀective than lithium alone. This
study, however, had a number of methodological
limitations, including an open design; hence, these
ﬁndings need to be conﬁrmed in double-blind trials
before ﬁrm conclusions can be drawn.
Lamotrigine. During a one-year extension phase of
an RCT, median time to relapse or recurrence was
longer among responders receiving lamotrigine
compared to those receiving placebo as an addon to lithium ± paroxetine (ten versus 3.5months)
(164).
An open, randomized trial in patients with BD I
found no diﬀerences in maintenance eﬀectiveness
between lithium (n = 78) and lamotrigine (n = 77)
(165). Among patients followed for at least ﬁve
years, practically no patients were maintained
successfully on monotherapy with either drug.
Olanzapine. A meta-analysis of ﬁve RCTs found that
olanzapine as monotherapy or an adjunct to lithium
or divalproex was more eﬀective than adjunct
placebo in preventing a manic, but not any type of
depressive, episode (166). The analysis concluded
that olanzapine may prevent manic episodes only in
patients who have responded to olanzapine for an
acute episode and who have not previously had a
satisfactory response to lithium or valproate.
In two recent RCTs, olanzapine was included as
an active control arm, and in the continuation
phase demonstrated a signiﬁcantly longer time to
recurrence than either risperidone LAI (167) or
paliperidone ER (168).
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A large, observational study (EMBLEM) included 1076 patients in a comparison of olanzapine
monotherapy or as an adjunct and found no
signiﬁcant diﬀerence in rates of improvement,
remission, or recovery, but signiﬁcantly lower
relapse rates with olanzapine alone compared to
adjunctive olanzapine (p = 0.01) over the twoyear follow-up (169).
Quetiapine. Three of the ﬁve large RCTs described
in the 2009 guidelines (3), which demonstrated the
eﬃcacy of quetiapine alone or in combination with
lithium ⁄ divalproex for maintenance therapy in
BD, have now been published (level 1) (170–172).
The eight-week acute-phase results of the EMBOLDEN I (90) and II (91) trials have also been
published but the long-term data remain available
only in abstract form.
Risperidone LAI. Risperidone LAI monotherapy
(level 2) (173) and adjunct (level 2) (174) were
previously recommended as ﬁrst-line maintenance
therapies (3), based on RCTs presented in abstract
form that have now been published. An additional
18-month continuation study has now provided
level 1 evidence for maintenance risperidone LAI.
Time to recurrence of any mood episode was
signiﬁcantly longer with risperidone LAI compared
to placebo (level 1) (168). However, risperidone
LAI was less eﬀective in preventing relapse
compared to olanzapine.
In addition, a small (n = 29), long-term, open
trial demonstrated improvements in treatment
adherence, reductions in any relapse rates, and
reductions in re-hospitalization rates with adjunctive risperidone LAI during a mean two-year
follow-up (175).
Aripiprazole. Aripiprazole monotherapy has demonstrated eﬃcacy for the prevention of manic
episodes in the maintenance treatment of patients
with BD I and was included in the 2009 guideline
as a ﬁrst-line maintenance therapy for the treatment and prevention of mania (level 1) (3).
A 52-week, relapse prevention RCT demonstrated the eﬃcacy of aripiprazole as an adjunct to
lithium or divalproex in patients with manic ⁄ mixed
episodes and an inadequate response to lithium or
divalproex (176). Patients (n = 337) in remission
for 12 weeks who were randomized to continue
adjunctive aripiprazole had a lower rate of relapse
to manic (5% versus 15%, p = 0.013) but not
depressive (10% versus 13%, p = 0.384) episodes.
Since adjunctive aripiprazole demonstrated eﬃcacy
for the prevention of any mood episode or manic
episodes, but not depressive episodes, it has been

added as a ﬁrst-line maintenance therapy for the
prevention of manic episodes (level 2).
Another 52-week relapse prevention study in 351
BD I patients with a manic ⁄ mixed episode, available in abstract form, showed a non-signiﬁcant
trend to lower rates of manic ⁄ mixed relapse with
aripiprazole versus placebo added to lamotrigine
(11% versus 23%, p = 0.058) (177). There was a
non-signiﬁcant trend to lower rates of any relapse,
and no eﬀect on depressive relapse rates.
Ziprasidone. An RCT demonstrating the eﬃcacy of
adjunctive ziprasidone for maintenance treatment
of BD, previously available in abstract form, has
now been published (level 2) (178). Adjunctive
ziprasidone (80–160 mg ⁄ day) demonstrated eﬃcacy for the prevention of manic, but not depressive, episodes.
Second-line options:
Carbamazepine. A meta-analysis of four RCTs,
including 464 patients, supports previous conclusions that maintenance treatment with carbamazepine has a similar eﬃcacy to lithium for rates of
relapses, with the caveat that there were fewer
withdrawals due to adverse eﬀects with lithium
(level 2) (179). Given the signiﬁcant tolerability
issues with carbamazepine and the diﬃculty in
combining this agent with other psychotropic
medications because of its hepatic microsomal
enzyme induction properties, carbamazepine continues to be recommended as a second-line option.
OFC. A six-month, continuation, RCT comparing
OFC and lamotrigine monotherapy in patients
with bipolar depression that was previously cited in
abstract form has now been published (94). OFC
was associated with a signiﬁcantly greater improvement in depressive and manic symptoms, but there
were no diﬀerences in relapse rates of bipolar
depression among responders to acute treatment.
In the observational EMBLEM study in 1076
patients with BD mania, adjunctive olanzapine was
less eﬀective than olanzapine monotherapy in
preventing any relapse (169). By contrast, another
study of open-label continuation treatment, in 114
patients with bipolar depression who were responders to OFC found that signiﬁcantly more
patients maintained their response to OFC compared to olanzapine monotherapy (180).
Paliperidone ER. In a three-month continuation
study, continued paliperidone ER was signiﬁcantly
more eﬀective than placebo in preventing relapse in
prior paliperidone ER responders (level 2) (168).
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However, paliperidone ER was less eﬀective in
preventing relapse compared to the olanzapine
active control group.
Third-line options:
Asenapine. Nine-week and 40-week extension
phase results from two pooled three-week RCTs
demonstrated the maintenance of beneﬁts with
asenapine monotherapy and olanzapine in patients with BD mania (YMRS reduction )24.4
and )23.9 at week 12, )28.6 and )28.2 at week
52, respectively) (level 2) (58, 59). At one year, a
worsening of mania was reported in 2.6% of
asenapine patients and 1.9% of olanzapine
patients, while a switch to a depressive episode
occurred in 0% of asenapine and 3.0% of
olanzapine patients (59). Time to response was
signiﬁcantly longer with asenapine compared to
olanzapine (p = 0.0127). In this trial, patients in
the placebo groups of the original RCTs were
blindly switched to asenapine.
In addition, 40-week extension phase results
have now been reported in abstract form from
the trial of adjunctive asenapine added to lithium ⁄ divalproex compared to placebo (62). Of the
original 318 patients, 71 completed the 40-week
extension; improvements in mania ()17.2 versus
)19.7) and depression ()3.3 versus )3.9) scores at
52 weeks were seen in both the asenapine and
placebo groups, but the extension was not powered
for statistical comparisons.
Based on evidence of maintenance of beneﬁts,
but in the absence of relapse prevention data and
clinical experience, asenapine is recommended as a
third-line option for maintenance therapy.
Rapid cycling

In a six-month RCT, patients with BD (recent manic
episode), SUD, and rapid cycling, who were
responders to lithium plus divalproex, were randomized to continue combination therapy or lithium
alone (181). Of 149 patients enrolled into the openlabel acute stabilization phase, 31 were assigned to
maintenance treatment and 55% relapsed. There
were no signiﬁcant diﬀerences between combination
and monotherapy in the rate of relapse or time to
relapse. However, given the small sample size, the
study was likely underpowered to detect this.
In the STEP-BD study, among patients who
were responders to adjunctive antidepressants and
continued this treatment, those with a rapidcycling course had three times more depressive
episodes compared to those without rapid cycling
(1.29 versus 0.42 episodes ⁄ year, p = 0.04) (182).
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Mixed states

Several open-label and post-hoc analyses provide
additional insight into the role of atypical antipsychotic agents in the management of patients with
mixed episodes or psychotic symptoms. In a posthoc analysis of patients with mixed episodes
(n = 121), where responders to olanzapine were
randomized to continue olanzapine or switch to
placebo, there were signiﬁcant reductions in relapse
rates with olanzapine compared to placebo (59.2%
versus 91.1%, p < 0.001) (183). During 52 weeks
of ﬂexible-dosed ziprasidone (40–160 mg ⁄ day)
open-label extension treatment (n = 65), patients
with manic or mixed episodes, with or without
psychotic symptoms, showed comparable improvements in mania and overall subtypes across
subgroups (184). In a 24-week, open-label trial of
adjunctive risperidone in 114 patients with mixed
or manic episodes, signiﬁcant reductions from
baseline in manic, depressive, and overall symptom
scores were observed with combination therapy in
both the manic and mixed groups (185).
Section 6. Special populations

Issues in the management of BD in women

The management of BD in women can present
additional challenges associated with the reproductive cycle.
Premenstrual syndrome (PMS) ⁄ premenstrual dysphoric disorder(PMDD): In the longitudinal STEPBD study, among women with BD (n = 293),
those with premenstrual exacerbation had more
episodes (primarily depressive), more depressive
and manic symptoms overall, a shorter time to
relapse, and greater symptom severity (186). Premenstrual exacerbation may predict a more symptomatic and relapse-prone phenotype in women
with BD.
A study in 61 women with BD I or BD II and
122 healthy women found that moderate-to-severe
PMS ⁄ PMDD occurred signiﬁcantly more frequently in patients with BD II (51.6%) compared
to the healthy women (19.7%) (187). Similarly, in a
study of 92 women with BD I or BD II, patients
with PMDD were more likely to have BD II and
cyclothymia than were patients without PMDD
(188).
Among patients seen at a specialty gynecology
clinic for chronic pelvic pain, those with endometriosis (n = 27) were more likely to have BD (44.4%)
and a poorer quality of life than women with nonendometriosis pelvic pain (n = 12) (0%) (189).
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Pre-conception: Providing appropriate education
and guidance to patients considering pregnancy or
who may have recently become pregnant is
an important component of BD management.
Pre-conception counseling should include a careful
review of risks and beneﬁts and a treatment
plan for ongoing monitoring. An analysis of a
large claims database including 16385 women of
child-bearing age with BD or MDD revealed 1308
women who were receiving a category D (12%) or
category X (1%) medication during pregnancy
(190). The most frequently used psychotropic
drugs were paroxetine, alprazolam, lorazepam,
divalproex, lithium, and temazepam.
Pregnancy: The management of pregnant women
with BD should incorporate careful planning.
Updated recommendations on the use of psychiatric medications during pregnancy and lactation are
available from the American Congress of Obstetricians and Gynecologists (ACOG), and the reader is referred to this Practice Bulletin for more
information (191). In addition, please visit the
Canadian Hospital for Sick Children Motherisk
website (http://www.Motherisk.org). Therefore, in
the following section, we will provide only a brief
update of some of the new data in patients with
BD.
The risk of teratogenicity associated with use
of psychotropic medications (please see ACOG
recommendations in Table 6.2) during the ﬁrst
trimester should be carefully weighed against the
risks to the mother and the fetus of an untreated
mood episode. Psychotropic medications can be
used in the second and third trimester if necessary.
If lithium is used during the second and third
trimester, the serum lithium levels should be
monitored closely because of changes in blood
volume during pregnancy, and the dose should be
adjusted accordingly to maintain levels in the
therapeutic range.
Cohort studies in various patient populations
conﬁrm the teratogenic risk associated with
divalproex (192–194) and carbamazepine (195)
during pregnancy. In a case-controlled series of
52 pregnancies, topiramate was associated with
reduced birth weight but no decrease in gestational
age and no increase in structural defects (196).
Several cohort studies in various patient populations found that, during pregnancy, antidepressants did not confer an increased risk of major
congenital anomalies compared to unexposed
controls (197, 198). However, in one analysis
antidepressant use was associated with increased
rates of pregnancy complications, including induced delivery, caesarean section, and preterm

birth, as well as increased risk of persistent
pulmonary hypertension of the newborn (199).
Some analyses suggest increased risks with
individual antidepressants (198–200), while others
do not (197). In one analysis, there were associations of ﬂuoxetine with ventricular septal defects,
paroxetine with right ventricular outﬂow tract
defects, and citalopram with neural tube defects,
although the absolute risk for these speciﬁc eﬀects
was small (198). The rate of major anomalies
(primarily cardiovascular) in birth outcome among
pregnant patients (n = 314) with ﬁrst trimester
exposure was 4.7% with ﬂuoxetine and 5.2%
with paroxetine, compared to 2.5% in control
patients (n = 1467), in a multicentre, prospective,
controlled study (200). Cardiovascular defects have
also been associated with paroxetine (199, 201) and
tricyclic antidepressant exposure (199).
A Canadian neonatal record analysis (n =
119547 live births) concluded that prenatal exposure to combination therapy with SSRI and
benzodiazepines conferred a higher incidence of
congenital heart disease when compared to no
exposure (202). SSRI monotherapy was not associated with an increased risk for major congenital
anomalies, but was associated with an increased
incidence of atrial septal defects.
A retrospective chart review including 30092
total deliveries identiﬁed one major malformation
among 16 of the mothers who were treated with
atypical antipsychotic agents during their pregnancy (203). The Food and Drug Administration
(FDA) issued a safety alert regarding the risks to
newborns associated with prenatal exposure to
typical or atypical antipsychotic drugs (204). The
new drug labels now contain information about the
potential risk for abnormal muscle movements and
withdrawal symptoms including agitation, abnormal muscle tone, tremor, sleepiness, breathing, and
feeding diﬃculties in newborns.
In an observational, prospective study in 14
women with BD undergoing maintenance treatment with lithium during pregnancy, the lithium
concentration ratio from infant to mother was 0.96
and congenital malformations were greater in those
receiving higher doses versus lower doses; however,
no signiﬁcant diﬀerences in neonatal outcomes
(gestational age ⁄ weight, Apgar scores, or hospital
stay) were noted (205).
Postpartum period: Distinguishing bipolar depression from MDD can be challenging in the
postpartum period because of a lack of screening
instruments designed speciﬁcally for use during this
period (206). A Mood Disorder Questionnaire
(MDQ) validation study concluded that, with
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Table 6.2. Psychiatric medications in pregnancy and lactation

Agent

Pregnancy risk
categorya

Anxiolytic medications
Benzodiazepines
Alprazolam
D
Chlordiazepoxide
D
Clonazepam
D
Clorazepate
D
Diazepam
D
Lorazepam
D
Oxazepam
D
Benzodiazepines for insomnia
Estazolam
X
Flurazepam
X
Quazepam
X
Temazepam
X
Triazolam
X
Non-benzodiazepine anxiolytics and hypnotics
Buspirone
B
Chloral hydrate
C
Eszoplicone
C
Zaleplon
C
Zolpidem
B
Antiepileptic and mood-stabilizing medications
Lithium carbonate
D
Valproic acid
D
Carbamazepine
D
Lamotrigine
C
Antidepressants
Tricyclic and heterocyclic antidepressants
Amitriptyline
C
Amoxapine
C
Clomipramine
C
Desipramine
C
Doxepin
C
Imipramine
C
Maprotiline
B
Nortriptyline
C
Protriptyline
C
Selective serotonin reuptake inhibitors
Citalopram
C
Escitalopram
C
Fluoxetine
C
Fluvoxamine
Paroxetine
Sertraline
Other antidepressants
Bupropion
Duloxetine
Mirtazapine
Nefazodone
Trazodone
Venlafaxine
Antipsychotic medications
Typical antipsychotic agents
Chlorpromazine
Fluphenazine
Haloperidol
Loxapine
Perphenazine
Pimozide
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American Academy of
Pediatrics rating

Lactation risk
categoryb

Unknown, of concern
N ⁄A
N ⁄A
N ⁄A
Unknown, of concern
Unknown, of concern
N ⁄A

L3
L3
L3
L3
L3, L4 if used chronically
L3
L3

N ⁄A
N ⁄A
Unknown, of concern
Unknown, of concern
N ⁄A

L3
L3
L2
L3
L3

N ⁄A
Compatible
N ⁄A
Unknown, of concern
N ⁄A

L3
L3
N ⁄A
L2
L3

Contraindicated
Compatible
Compatible
Unknown

L4
L2
L2
L3

Unknown,
Unknown,
Unknown,
Unknown,
Unknown,
Unknown,
N ⁄A
Unknown,
N ⁄A

L2
L2
L2
L2
L5
L2
L3
L2
N ⁄A

of
of
of
of
of
of

concern
concern
concern
concern
concern
concern

of concern

N ⁄A
N ⁄A
Unknown, of concern

C
D
C

Unknown, of concern
Unknown, of concern
Unknown, of concern

L3
L3 in older infants
L2 in older infants, L3 if used in
neonatal period
L2
L2
L2

B
C
C
C
C
C

Unknown, of concern
N ⁄A
N ⁄A
N ⁄A
Unknown, of concern
N ⁄A

L3
N ⁄A
L3
L4
L2
L3

C
C
C
C
C
C

Unknown, of concern
N ⁄A
Unknown, of concern
N ⁄A
Unknown, of concern
N ⁄A

L3
L3
L2
L4
N ⁄A
L4
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Table 6.2. (Continued).

Agent
Thioridazine
Thiothixene
Trifluoperazine
Atypical antipsychotic agents
Aripiprazole
Clozapine
Olanzapine
Quetiapine
Risperidone
Ziprasidone

Pregnancy risk
categorya

American Academy of
Pediatrics rating

Lactation risk
categoryb

C
C
C

N ⁄A
N ⁄A
Unknown, of concern

L4
L4
N ⁄A

C
B
C
C
C
C

N ⁄A
Unknown, of concern
N ⁄A
Unknown, of concern
N ⁄A
Unknown, of concern

L3
L3
L2
L4
L3
L4

[Copyright (2008) Wolters Kluwer Health; reprinted with permission from (191)]. N ⁄ A = not available.
The US Food and Drug Administration classifies drug safety using the following categories: A = controlled studies show no risk; B = no
evidence of risk in humans; C = risk cannot be ruled out; D = positive evidence of risk; X = contraindicated in pregnancy.
b
Lactation risk categories are listed as follows: L1 = safest; L2 = safer; L3 = moderately safe; L4 = possibly hazardous; L5 = contraindicated.
a

alternate scoring, the MDQ may be a useful
screening instrument for BD in the postpartum
period (206, 207). The optimal cut-oﬀ score was
eight or more endorsed symptoms without the
supplementary questions (sensitivity 88% and
speciﬁcity 85%) (208).
In a well-designed longitudinal study involving
344 pregnant women, there was an 8.4-fold
increase in hypomanic symptoms in the early
postpartum period (11.7%) compared to during
the ﬁrst trimester (1.4%) and to eight weeks
postpartum (4.9%) (209). Although hypomanic
symptoms are common in the early puerperium,
they are often overlooked, leading to a misdiagnosis of MDD (210). This may be due in part to the
absence of hypomania from the postpartum-onset
speciﬁer in the Diagnostic and Statistical Manual
of Mental Disorders, 4th edition–text revised
(DSM-IV-TR) (211). However, a study from
Spain suggested reconsideration of the DSM
postpartum-onset speciﬁer, as it did not appear
to inﬂuence prognosis or functioning in women
with BD (212).
According to a Danish population-based study
of new mothers, the period of highest risk for
psychiatric readmission was 10 to 19 days postpartum [relative risk (RR) = 2.7], and the period
of lowest risk was during pregnancy (RR = 0.5).
Previous diagnosis of BD was the strongest
predictor of readmissions 10–19 days postpartum
(RR = 37.2), with 27% of women with BD
being readmitted within the ﬁrst year (213).
Similarly, psychotic illness has been shown to
peak immediately following a ﬁrst childbirth
(214).
ACOG recommendations for the use of psychiatric medications during lactation are also shown
in Table 6.2 (191).

Menopause: In a STEP-BD analysis of 164 patients
with BD followed for an average of 30 months,
menopausal transition was associated with significantly more visits due to depressive symptoms and
fewer euthymic visits compared to a comparison
group of non-menopausal women and men (215).
Issues in the management of BD in children and
adolescents

Complete treatment recommendations for pediatric BD are beyond the scope of these guidelines; the
reader is referred to speciﬁc guidelines for the
management of children and adolescents with BD,
such as those developed by the American Academy
of Child and Adolescent Psychiatry (AACAP)
(216). Therefore, in the following section, we will
provide only a brief overview of some of the issues
in this population without oﬀering recommendations for levels of treatment.
Presentation and diagnosis: Across the world, BD is
the fourth leading cause of disability among
adolescents (15–19 years) (217). The presentation
and diagnosis of BD in children and adolescents
remains controversial. Increasing billing and discharge diagnoses of pediatric BD contradict a
stable epidemiologic prevalence, suggesting that
diagnostic criteria for BD may not be systematically applied in some clinical settings (218, 219).
However, much of the controversy regarding
pediatric BD has focused on the group of youth
with severe, chronic, non-episode irritability, which
has led to the proposed DSM-5 diagnosis of
Ôdisruptive mood dysregulation disorderÕ (DMDD)
(220). The reader is referred to recent publications
focusing speciﬁcally on diﬀerential diagnosis and
developmental considerations in ascertaining
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manic symptoms (221, 222), and regarding concerns about the DMDD diagnosis (223). Prospective studies of children and adolescents with
rigorously deﬁned BD demonstrate that this is an
episodic illness that continues into young adulthood and is characterized by substantial impairment and morbidity (224–226).
Based on a meta-analysis of 12 epidemiological
studies in patients between the ages of seven and
21 years (n = 16222), the overall prevalence of BD
was 1.8% (219). Of note, rates of BD in these
epidemiologic studies did not increase over time
and did not diﬀer for studies within versus outside
of the USA. Among Canadian adolescents and
young adults (15–24 years), the CCHS 1.2 survey
recorded a lifetime prevalence of BD of 3.0%
(2.1% in those aged 15–18 years; 3.8% in those
aged 19–24 years) (227). In a claims database, the
one-year rate of a new diagnosis of BD among
patients £17 years of age was 0.23%. Misdiagnosis
was common, with 47% being diagnosed with
depressive disorder and 37% with disruptive
behavior disorder in the previous year (228). In
the Course and Outcome of Bipolar Youth
(COBY) study (n = 364), ﬁrst episodes in patients
‡ 12 years were generally depressive, while those in
patients <12 years were more likely to be subsyndromal manic ⁄ hypomanic symptoms (229).
A claims analysis of younger (age 6–18 years)
patients with BD (n = 423) showed that the
majority did not receive guideline-concordant care,
with only 26% receiving anti-manic treatments and
33% receiving antidepressant monotherapy (230).
Similarly, eight-year follow-up data from an
NIMH study on the course of BD I in children
found that 37% of patients had never received
anti-manic treatment (231).
Over a ﬁve-year follow-up period in the COBY
study (n = 413) in youth (age 7–17 years), the rate
of suicide attempts was 18%. (232). Predictive
variables included female gender, severity of
depressive symptoms, familial history of depression, and lifetime history of exposure to antidepressants. Non-suicidal self-injury has also been
reported in more than 20% of children and
adolescents with BD (233).
Comorbidities and mimics: In the COBY study,
44% of youth had at least one lifetime anxiety
disorder, and nearly 20% had two or more, with
the most prevalent being separation anxiety (24%)
and generalized anxiety disorder (GAD) (16%)
(234). A family history study that included 157
patients (age 6–17 years) with BD I revealed
extremely high rates of comorbid attention-deﬁcit
hyperactivity disorder (ADHD) (85%), oppositional
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deﬁant disorder (90%), two or more anxiety
disorders (64%), conduct disorder (51%), and
SUD (12%) (235).
Early BD onset (age <12 years) has been associated with ADHD, whereas later BD onset (age
‡ 12 years) was associated with panic, conduct, and
SUD (229). Psychotic symptoms have been reported in about one-third of youth with BD, and
confer a signiﬁcantly greater likelihood of lifetime
GAD, agoraphobia, social phobia, and obsessive
compulsive disorder (OCD) (236).
Medical comorbidities including obesity, type 2
diabetes mellitus, other endocrine disorders,
migraine headaches, central nervous system disorders ⁄ epilepsy, organic brain disorders ⁄ mental
retardation, cardiovascular disorders, and asthma
in a large cohort study were signiﬁcantly more
prevalent among children and adolescents with
BD (n = 1841) compared to a control group
(n = 4500) (237). In the COBY study (n = 348),
overweight ⁄ obesity was seen in 42% of youth with
BD, and was associated with increased psychiatric
burden (238). Moreover, in a pilot study on
inﬂammatory markers among 30 adolescents in
the COBY study, 40% had levels of high-sensitivity
C-reactive protein that are considered to confer a
high risk for cardiovascular disease among adults
(‡ 2 lg ⁄ mL) (239).
Acute and maintenance treatment of pediatric BD:
Most RCTs in youth with BD have investigated the
acute treatment of manic ⁄ mixed symptoms, with
few assessing maintenance therapy. Thus, taking
into account that not all treatments that are
eﬃcacious in adults will also be so in children
and adolescents, and until further studies become
available, the guidelines developed for adults with
BD should be cautiously applied to youth.
Psychosocial interventions
The two-year follow-up results of an RCT in
adolescent patients (n = 58) with BD which compared adjunctive family-focused treatment (FFT)
and enhanced care found no diﬀerences in time to
recurrence of depression or mania, but patients in
the FFT group spent fewer weeks in depressive
episodes (240). In a one-year open trial, a modiﬁed
FFT was associated with improved depression,
hypomania, and psychosocial functioning scores in
youth who were thought to be at high risk for
developing BD (241). Preliminary ﬁndings suggest
that child and family-focused CBT (242), dialectical behavior therapy (DBT) (243), and IPSRT
(244) may be promising in the management of BD
in this patient population.
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Pharmacological management
Atypical antipsychotics. The AACAP published a
practice parameter on the use of psychotropic
medication in children and adolescents, and the
reader is referred to those guidelines for more
details (245). Provided below is an overview of
current data of the eﬃcacy of atypical antipsychotic agents for the treatment of BD in younger
patients.
The US FDA has now approved quetiapine for
the ﬁrst-line treatment of acute manic ⁄ mixed
episodes in pediatric patients. In light of safety ⁄ tolerability concerns, olanzapine (weight gain and
metabolic disturbances) and ziprasidone (QT prolongation) were approved as second-line treatments only (246).
A meta-analysis of nine RCTs included 1609
pediatric patients with acute BD mania and found
signiﬁcantly greater improvements in YMRS
scores in the atypical antipsychotic agent group
and mood stabilizer group relative to placebo. The
eﬀect sizes were greater for the atypical antipsychotic agent group compared to a mood stabilizer
group (eﬀect size 0.65 versus 0.20). However, the
mood stabilizer group included studies on topiramate and oxcarbazepine, neither of which demonstrated eﬃcacy as mood stabilizers. Further,
medication-associated weight gain was greater with
atypical antipsychotic agents than with mood
stabilizers (eﬀect size 0.53 versus 0.10) (44).
In a small eight-week RCT in 32 adolescents (age
12–18 years), quetiapine monotherapy was not
signiﬁcantly better than placebo for the treatment
of bipolar depression (247). This negative trial
requires replication in light of the small sample
size, high placebo response rates, and robust
evidence of quetiapine eﬃcacy in bipolar depression in adults group (1–3). Quetiapine monotherapy
has also demonstrated eﬃcacy as acute and maintenance treatment in small, open-label studies (248,
249).
A pooled analysis of four olanzapine trials
(two RCTs, two open-label) in adolescents (age
13–17 years) with BD or schizophrenia revealed
signiﬁcantly more weight gain compared to adult
patients (7.4 kg versus 3.2 kg) in up to 32 weeks
of treatment (250). Adolescents also experienced
signiﬁcant changes in fasting glucose, total cholesterol, triglycerides, alanine aminotransferase, and
prolactin. In an eight-week, open-label study the
addition of topiramate to olanzapine therapy in 40
pediatric patients with BD resulted in signiﬁcantly
less weight gain than with olanzapine monotherapy, with no diﬀerences in mania symptom scores
(251).

In addition to the previously cited RCT data,
further open-label data support the eﬃcacy and
tolerability of ziprasidone therapy in youth with
BD (252, 253).
A three-week RCT in 169 pediatric patients with
BD mania ⁄ mixed episodes demonstrated greater
reductions in mania scores with risperidone versus
placebo (254). In a six-week RCT in 66 youth,
risperidone resulted in more rapid improvement in
manic symptoms and a signiﬁcantly greater rate of
remission (63% versus 33%) compared to divalproex (255). Primary outcomes from the eight-week
Treatment of Early-Age Mania (TEAM) study of
279 medication-naı̈ve youth (age 6–15 years)
with BD I mania ⁄ mixed episodes were recently
published (256). TEAM was a controlled, randomized, no-patient-choice study comparing lithium,
divalproex, and risperidone. The response rate for
risperidone (68.5%) was signiﬁcantly greater than
for lithium (35.6%) and divalproex (24.0%), which
did not diﬀer signiﬁcantly from each other. However, increased weight gain, body mass index (BMI),
and serum prolactin levels were also signiﬁcantly
greater with risperidone than with the other medications. Similar results were seen in a small cohort
study in which risperidone resulted in a faster and
greater reduction of symptom scores versus divalproex (257). Hence, although it is premature to
conclude that atypical antipsychotic agents have
greater eﬃcacy than mood stabilizers in pediatric
mania, a convergence of data suggest that this may
be the case.
An RCT demonstrating the eﬃcacy of aripiprazole for BD I manic ⁄ mixed episodes in pediatric
patients that was previously cited in abstract form
has now been published (258). Another six-week
RCT in 43 pediatric patients with BD manic
⁄ mixed episodes and comorbid ADHD demonstrated signiﬁcant reductions in manic, but not
depressive or ADHD, symptoms with aripiprazole
versus placebo (level 1) (259).
Analyses suggest a poorer response to atypical
antipsychotic agent therapy in pediatric patients
with BD and comorbid OCD, but not in those with
comorbid autism (260, 261).
Anticonvulsants. Several small, open-label trials
demonstrated signiﬁcant improvements with lamotrigine monotherapy in both manic and depressive
clinical endpoints (262, 263), and as an adjunct to
atypical antipsychotic agents (264) in youth with
BD mania ⁄ mixed episodes during 3–6 months of
follow-up.
A four-week RCT of divalproex ER in 150
pediatric patients (age 10–17 years) with BD
mania ⁄ mixed episodes found no beneﬁt of active
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treatment over placebo on primary or secondary
outcomes, and there was only modest improvement
in mania scores during the six-month, open-label
extension phase (265). However, a six-month, openlabel study in 226 youth with BD I mania ⁄ mixed
episodes found that divalproex ER reduced mania
scores and was generally well tolerated (266).
In an eight-week, open-label trial in 27 youth
with bipolar spectrum disorders, carbamazepine
ER was associated with improvements in mania,
depression, psychosis, and ADHD symptoms, but
drop-out rates were high (267).
Issues in the management of BD in older patients

Presentation and course: The two-year EMBLEM
study included 475 patients >60 years with acute
BD mania ⁄ mixed, and found that older patients
had a history of more rapid cycling, fewer suicide
attempts, and less severe manic and psychotic
symptoms, but no diﬀerence in depressive symptomatology (268). Older patients with late-onset
BD (age ‡ 50 years) experienced a better 12-week
outcome with a faster recovery and earlier discharge compared to older patients with early-onset
BD (age <50 years). The prevalence of mixed
episodes was reported at 10% in patients
‡ 60 years in an RCT (269).
Comorbidity: In a case-controlled study, there was
a higher prevalence among older patients (n = 82,
age >60 years) with BD of diabetes mellitus
(27%), atopic diseases (20%), smoking (24%),
and unfavourable social functioning (22%) when
compared to age-matched controls (270).
A large survey of geriatric patients in a Veterans
Health Administration database found the use of
anticonvulsants to be associated with an over
twofold increased risk of fracture. In addition,
patients with BD had a 20% increased risk of
fracture compared to those without BD, independent of the use of anticonvulsants (271).
Older adults with BD have been shown to have
greater levels of cognitive dysfunction than
age-matched mentally healthy control subjects
(272–275). Among older patients with BD, a
greater burden from vascular risk factors has been
associated with poorer outcomes on some cognitive
measures (276, 277). Several analyses have failed to
detect a signiﬁcant association between dementia
or cognitive performance in older patients and the
use of lithium (277, 278).
Treatment of BD in older patients: Data assessing
pharmacotherapy speciﬁcally in older patients
with BD remain scarce. In a post-hoc, pooled
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analysis of two quetiapine monotherapy RCTs
in patients with acute BD mania, subgroup
analysis of 59 older adults (age ‡ 55 years) demonstrated a signiﬁcant improvement in manic
symptoms as early as day four, and this was
sustained over the 12 weeks of follow-up versus
placebo (279).
At 12 weeks, the results from an open-label
study of adjunctive lamotrigine in older patients
(n = 57, age ‡ 60 years) with BD I or BD II
indicated an overall signiﬁcant decline in depressive symptoms, with a 65% response rate and a low
rate of discontinuations because of adverse events
(10%) (280).
Issues in the management of BD in patients with comorbid
conditions

The reader is also referred to a task force report on
the management of patients with mood disorders
and comorbid psychiatric and medical conditions
developed by the CANMAT Comorbidity Task
Force (281).
Prevalence and impact
Medical. In the large US National Epidemiologic
Survey on Alcohol and Related Conditions study,
which included 1548 patients with BD I, the
prevalence of one or more general medical conditions was 32% (282). In another analysis,
patients with BD I or BD II were found to have
a mean of 2.5 comorbid medical conditions (283).
Cardiovascular disease and hypertension were
almost ﬁvefold more prevalent among patients
with BD than controls (284). The risk of cardiovascular mortality was found to be more than
double in patients with BD I compared to those
with BD II, in a long-term follow-up study (285).
In addition, patients with BD had a signiﬁcantly
greater risk for hospital readmission due to a
cardiovascular event (286).
The increased rate of metabolic syndrome in
patients with BD, by up to twofold compared to
the general population, has been documented in
countries around the world (287). Comorbid metabolic disturbances in patients with BD have been
associated with a more complex illness presentation, less favourable response to treatment, and
worse course of illness (283, 287, 288).
In patients with BD, a higher BMI has been
associated with more frequent manic and depressive relapses, more suicide attempts, and poorer
psychosocial functioning, as well as a greater
frequency of type II diabetes, hypertension, and
subthreshold anxiety disorders (289–291). Over-
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weight ⁄ obesity has also been shown to have a
negative impact on long-term treatment response
(283, 289) and on cognitive function in euthymic
patients with BD (292).
Comorbid migraine aﬀects nearly one in four
patients with BD (293), and confers signiﬁcantly
increased risk for suicidal behavior, comorbid
psychiatric disorders, and rapid cycling, as well as
a greater number of mood episodes and lifetime
hospitalizations compared to patients without
migraine (293, 294). The prevalence of migraine is
reportedly higher in patients with BD II than in
those with BD I (35% versus 19%) (293).
Up to 12% of patients with epilepsy may have a
diagnosis of BD; however, only 1.4% had pure BD,
as all other cases were associated with diﬀering states
relating to the primary diagnoses of epilepsy (295).
Psychiatric. A retrospective analysis of four trials
including 566 patients with rapid-cycling BD I or
BD II found lifetime rates of anxiety disorders and
SUD of 46% and 67%, respectively (296). Comorbid SUD has been linked to an increased risk
of suicide and other unnatural deaths, suicide
attempts, nicotine dependence, and other SUDs in
patients with BD (297–299). Patients with BD have
a ﬁvefold higher risk of current cigarette smoking
compared to the general population (300). Cigarette smoking has also been associated with
suicidal behavior in patients with BD (301, 302).
In addition, suicidal behavior has been associated
with borderline personality disorder (BPD), panic
disorder, alcoholism, other drug addictions, and
GAD, although only BPD and alcoholism were
independently associated (301). Comorbid SUD in
patients with BD confers substantially greater
impairment in social functioning compared to
patients without SUD (303).
In patients with rapid-cycling BD, comorbid
SUD was associated with a twofold increased risk
of being incorrectly medicated (not receiving a
mood stabilizer after the onset of ﬁrst mania ⁄ hypomania) (296). In addition, an uncontrolled study
suggested that comorbid SUD may be associated
with a very high risk of antidepressant-induced
switch to mania (76%) (304, 305).
A functional assessment of patients (n = 206)
with BD I or BD II noted that more than one-third
had missed ‡ 2 years of work time over a ﬁve-year
period, and extended unemployment was associated
with increased rates of panic disorder and alcohol
abuse (306). The presence of comorbid panic disorder in patients with BD I (compared to those with no
panic disorder) was associated with signiﬁcantly
more depressive, manic, and any mood episodes, as
well as increased risk of lifetime SUD or eating

disorders (307). In the NIMH Collaborative Depression Study, the presence of psychic and somatic
anxiety symptoms was associated with a greater
proportion of weeks in depressive episodes during
long-term follow-up (mean 17 years) of patients
with BD (308). The prevalence of lifetime eating
disorders, particularly binge eating disorder, is high
(14%) in patients with BD (309).
It is of note that patients with BPD are at high
risk of being misdiagnosed as having BD, and vice
versa (310, 311).
The International Mood Disorders Collaborative Project reported the prevalence of lifetime
ADHD in adults with BD as 18%, which was
substantially higher than that found in patients
with MDD (5%). Comorbid ADHD has been
associated with a greater number of comorbid
psychiatric conditions (312), a negative impact on
the course of BD in adulthood (313), impaired
psychosocial functioning, and poorer overall quality of life (312, 314).
Treatment of BD in patients with comorbidities: In a
retrospective analysis, a bipolar collaborative
chronic care model was as eﬀective in patients
with BD and comorbid conditions (SUD, psychiatric, and ⁄ or medical) as in those without,
although it may be necessary to pay speciﬁc
attention to physical quality of life in patients with
cardiovascular disease (315). A six-month pilot
study of a BD medical care model demonstrated a
slowing of decline in physical health-related quality
of life compared with usual care in patients with
BD and cardiovascular disease-related risk factors
(316). Improvements in mental health-related quality of life were also seen, but were not signiﬁcant.
Medical. A small (n = 10), 14-week pilot study of
an integrated psychosocial treatment model
including three treatment modules (nutrition ⁄ weight loss, exercise, and wellness treatment)
administered in group sessions, as well as weekly
exercise, demonstrated improvements in quality of
life, depressive symptoms, and weight (317).
Open-label adjunctive ziprasidone was eﬀective
in signiﬁcantly improving weight-related parameters while maintaining or improving mood symptoms in 25 obese ⁄ overweight patients with BD
taking atypical antipsychotic agents, lithium, or
divalproex (318).
In a recent report, bariatric surgery for weight
reduction was as eﬀective in patients with BD as in
those without (319).
Psychiatric. An RCT in 61 patients with BD and
comorbid SUD compared a modiﬁed version of
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integrated group therapy (12 sessions instead of 20)
to group drug counseling (320). The integrated
group therapy, which employed a cognitive-behavioral model integrating treatment of both conditions, resulted in an increased likelihood of
achieving total abstinence and a better overall
composite outcome compared to regular group
counseling. A review of psychosocial interventions
for the treatment of comorbid anxiety in patients
with BD concluded that CBT, mindfulness-based
CBT, and relaxation training may be eﬀective,
while interpersonal and family therapy, and psychoeducation alone did not seem to be beneﬁcial in
treating comorbid anxiety (321).
Two large, 12-week RCTs (n = 362 and
n = 115) of adjunctive quetiapine in patients with
BD and comorbid alcohol abuse or dependence did
not show signiﬁcant improvements in measures of
alcohol use and dependence compared to placebo,
although depressive symptoms improved in one trial
(322, 323). A 12-week RCT of adjunctive naltrexone
in 50 patients with BD I or BD II and comorbid
alcohol dependence demonstrated a trend toward
greater decrease in alcohol-related outcomes compared to placebo (324). Response to naltrexone was
signiﬁcantly related to medication adherence.
In a 20-week RCT involving 80 patients with BD
and comorbid SUD (cocaine or methamphetamine
dependence), both quetiapine and risperidone
improved manic and depressive symptoms, as well
as drug cravings and use, with no signiﬁcant
diﬀerences between treatments (325); however, this
study lacked a placebo group. In another placebocontrolled, 12-week RCT, involving 44 patients with
BD I or BD II and cocaine dependence, citicoline
signiﬁcantly improved some aspects of declarative
memory and cocaine use, but not mood (326).
In a small RCT involving 31 patients with rapidcycling BD and comorbid SUD who were stabilized
on the combination of lithium plus divalproex, there
was no signiﬁcant diﬀerence in mood relapse rates
between patients randomized to continue combination therapy and those who received lithium alone
(181). An analysis of 98 patients from the acute
open-label phase of this study found that these

patients have a poor response to treatment and a
high burden of serious medical comorbidity (327).
A small, six-week RCT in 43 pediatric patients
with BD manic ⁄ mixed episodes and comorbid
ADHD demonstrated signiﬁcant reductions in
manic, but not depressive or ADHD, symptoms
with aripiprazole versus placebo (level 1) (259).
In a randomized, crossover trial in 16 youth with
BD (age 8–17 years) who had responded to
aripiprazole, the addition of methylphenidate did
not result in signiﬁcant improvements in ADHD or
mania symptoms compared to placebo (328);
however, depressive symptoms did improve.
In an eight-week RCT of risperidone in 111
patients with BD and comorbid panic disorder or
GAD, risperidone was no more eﬀective than
placebo on any of the anxiety measures (329).
A post-hoc analysis of the BOLDER I and
BOLDER II trials including 1051 patients with BD
I or BD II depression reported signiﬁcant improvements in anxiety symptom scores as early as week
one, and these were sustained through week eight
with quetiapine compared to placebo (330). This
suggests that quetiapine should be investigated in
patients with BD and comorbid anxiety disorders.
Section 7. Acute and maintenance management of
bipolar II disorder

Acute management of hypomania

The preponderance of depressive symptoms in
patients with BD II likely contributes to the
under-investigation of treatments for hypomania
in this patient group. The only studies carried out
to date examined mixed samples of patients with
BD I and BD II and did not report results
separately for BD II. Nonetheless, due to the
paucity of information on the treatment of hypomania, we will describe them brieﬂy here. Two
small, eight-week RCTs indicated that quetiapine
(n = 39) (331) and divalproex ER (n = 60) (332)
were superior to placebo in treating patients with
hypomania or mild mania. In addition, a previously described six-month, open-label trial suggested eﬃcacy for risperidone (333).

Table 7.2. Recommendations for pharmacological treatment of acute bipolar II depression
First line
Second line
Third line

Not recommended

Quetiapine, quetiapine XR a
Lithium, lamotrigine, divalproex, lithium or divalproex + antidepressants, lithium + divalproex, atypical
antipsychotic agents + antidepressants
Antidepressant monotherapy (primarily for those with infrequent hypomanias), switch to alternate
antidepressant, quetiapine + lamotrigine a, adjunctive ECT a, adjunctive NAC a,
adjunctive T3 a
See text on antidepressants for recommendations regarding antidepressant monotherapy

ECT = electroconvulsive therapy; NAC = N-acetylcysteine; T3 = triiodothyronine; XR = extended release.
a
New or change to recommendation.
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Due to the methodological limitations of these
trials, and the lack of systematic study of many
commonly used mood-stabilizing medications, it is
diﬃcult to formulate evidence-based treatment
recommendations for hypomania. However, clinical practice suggests that medications that are
eﬀective in mania are eﬃcacious in treating hypomanic symptoms. Thus, in patients with persistent
and ⁄ or impairing symptoms of hypomania, clinicians should treat according to their clinical
judgment, using lithium, divalproex, or atypical
antipsychotic agents and tapering potentially
contributory medications such as antidepressants.
Acute management of bipolar II depression

Psychotherapy: The role of psychotherapy in the
treatment of BD II depression has also been
understudied. Nonetheless, the predominance of
depressive symptoms in patients with BD II, and
the fact that BD II depression shares many clinical
characteristics with MDD suggest that psychotherapy may improve outcomes in these patients.
Supporting this is one small (n = 17), 12-week
feasibility study demonstrating that 41% of
patients with BD II depression achieved a response
(‡ 50% reduction in depression scores) with IPSRT
monotherapy without an increase in mania scores
(334).
Pharmacotherapy: Table 7.2 illustrates the recommendations for the pharmacological treatment of
acute BD II depression (1–3). Quetiapine XR joins
quetiapine as a ﬁrst-line option. Quetiapine plus
lamotrigine, adjunctive NAC, and adjunctive triiodothyronine (T3) have been added as third-line
options.
First-line options
Quetiapine. The four large RCTs demonstrating
the eﬃcacy of quetiapine monotherapy in combined groups of patients with BD I or BD II
depression, which were cited in previous iterations
of these guidelines, have now all been published:
BOLDER I (88) and II (89), and EMBOLDEN I
(90) and EMBOLDEN II (91). A pooled analysis
of data in 776 patients with BD II from all four
studies has been presented in abstract form (level 1)
(335). Quetiapine doses of 300 mg ⁄ day and
600 mg ⁄ day were both associated with signiﬁcantly
greater improvements in MADRS total scores
compared to placebo, beginning at week one and
continuing through week eight. Response and
remission rates were also signiﬁcantly greater with
both doses of quetiapine than placebo. There were

signiﬁcant improvements in core depressive symptoms, including reported sadness, anhedonia, negative thoughts, and suicidality, as well as anxiety
symptoms.
In an eight-week RCT in patients with BD I and
BD II depression, among the patients with BD II
(n = 53), quetiapine XR 300 mg ⁄ day was associated with a signiﬁcantly greater improvement in
MADRS total score at study end compared to
placebo (level 2) (92).
Second-line options
Lithium. The EMBOLDEN I trial included a
lithium comparator arm, and provides the only
placebo-controlled, parallel-group RCT data for
lithium in acute BD II depression (90). In this
trial, neither lithium nor quetiapine were superior
to placebo in improving depression scores in
patients with BD II, raising the possibility that
this was a failed, rather than negative, trial. In
addition, the mean lithium levels were
< 0.8 mEq ⁄ L.
Divalproex. A meta-analysis of four small studies
(total n = 142) in patients with BD I or BD II
depression found that the RR of response was
double, and of remission almost two-thirds greater,
with divalproex monotherapy compared to placebo
(96). Two of the trials reported results separately
for BD I and BD II, with one reporting greater
improvement in patients with BD I than BD II (as
outcomes for the BD II group showed no separation from placebo) (336), and the other reporting
greater improvements in BD II than BD I (337).
Additional, open-label data supporting the eﬃcacy
of divalproex ER in BD II depression, previously
cited in abstract form, have now been published
(338). Thus, the data in aggregate are mixed.
Further studies are clearly warranted to fully
understand the role of divalproex in BD II
depression.
Lamotrigine. The results of two previously unpublished RCTs of lamotrigine have been published in
a review article (339). In the ﬁrst study, 221
patients with BD II received lamotrigine
200 mg ⁄ day or placebo for eight weeks, while in
the second 206 patients with BD I or BD
II depression were randomized to lamotrigine
100–400 mg ⁄ day or placebo. In neither trial was
lamotrigine superior to placebo. The negative
results may be related to the slow titration of
lamotrigine and high placebo response rates.
Further, a meta-analysis of lamotrigine trials in
BD I or BD II depression showed greater response
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rates with lamotrigine than placebo, although the
eﬀect size was very modest (83). Based on this
evidence, and its excellent tolerability proﬁle,
lamotrigine continues to be recommended as a
second-line option for the acute treatment of BD II
depression.

Adjunctive ECT. An open-label study of twiceweekly bilateral ECT included patients with BD II
who were medication refractory (n = 67). They
achieved a response rate of 79% and a remission
rate of 57% (343). This response rate was intermediate between patients with MDD (94%) and
those with BD I (67%).

Third-line options
Antidepressant monotherapy. Relatively few studies have assessed antidepressant monotherapy in
BD II because of concerns about induction of
mood elevation. A paroxetine comparator arm in
the EMBOLDEN II trial represents the largest
placebo-controlled sample to evaluate antidepressant monotherapy in BD II depression (91).
Paroxetine was not superior to placebo, although
the dose may be considered low (20 mg), and
quetiapine did not separate from placebo in this
study, suggesting that this was a failed, rather
than negative, study. Interestingly, switch rates
into hypo ⁄ mania were similar with paroxetine
and placebo.
In a 14-week, open-label study of ﬂuoxetine
monotherapy (n = 148), 60% of patients responded
and 58% remitted (340). Although about 24%
experienced hypomania ⁄ subsyndromal hypomania, this did not result in treatment discontinuation. In a post-hoc analysis of a previously
reported open-label study in 83 patients with BD
II, the signiﬁcantly greater improvements in
depression scores with venlafaxine compared to
lithium were independent of rapid-cycling status,
and venlafaxine did not result in a higher proportion of mood conversions (versus lithium) in either
the rapid or non-rapid-cycling patients (341).
Patients in this study who were unresponsive to
lithium therapy (n = 14) and who were subsequently crossed over to venlafaxine experienced
signiﬁcantly greater reductions in depression and
overall mood scores, with no diﬀerences in mania
scores versus prior lithium (342). The main limitation of these studies is their open-label design.

Novel treatments. In a sub-analysis of a small
number of patients with BD II (n = 14) participating in a 24-week RCT, signiﬁcantly more
patients achieved full remission of both depressive
and manic symptoms with adjunctive NAC compared to placebo (344). In a retrospective chart
review of patients with treatment-resistant BD II
or BD NOS depression (n = 159), treatment with
supraphysiologic doses of T3 was associated with
response in a majority of patients (345).
Maintenance therapy for bipolar II disorder

Psychotherapy: A post-hoc analysis of 20 patients
with BD II who participated in a single-blind
RCT demonstrated the beneﬁts of adjunctive psychoeducation (21 sessions over six months) compared to unstructured support groups, with lasting
beneﬁts for up to ﬁve years (346). Signiﬁcantly
fewer patients in the psychoeducation group experienced any mood, depressive, or hypomanic
relapse during follow-up, and had signiﬁcantly
better psychosocial functioning at both two- and
ﬁve-year follow-up.
Pharmacotherapy: The major focus of maintenance
therapy for patients with BD II is prevention of
depressive episodes. New data support the addition
of quetiapine monotherapy as ﬁrst-line, and
adjunctive quetiapine as second-line options for
maintenance treatment for BD II (Table 7.4) (1–3).
Lithium and lamotrigine continue to be recommended as ﬁrst-line agents and ﬂuoxetine has been
added as a third-line treatment option.
First-line options

Quetiapine + lamotrigine. A 12-week, open-label
trial assessed the beneﬁt of adding lamotrigine or
quetiapine to pre-existing therapy in a mixed sample
of patients with BD (BD I n = 15, BD II n = 22, or
BD NOS n = 1) on multiple medications (level 3)
(104). Adding quetiapine to lamotrigine in patients
who had not responded to lamotrigine (n = 17
patients with BD II), and adding lamotrigine to
quetiapine in patients who had not responded to
quetiapine, was associated with improvements in the
overall sample (level 3) (104). Data were not
reported separately for patients with BD II.
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Quetiapine. A pooled analysis of maintenance data
from the EMBOLDEN I and II trials has been
presented in abstract form (335). Among patients
with BD II (n = 231) who achieved remission
during acute-phase treatment with quetiapine,
those who continued quetiapine monotherapy for
up to 52 weeks were signiﬁcantly less likely to
experience relapse into any mood episode [hazard
ratio (HR) 0.47 for 300 mg and 0.18 for 600 mg] or
depressive mood episode (HR 0.35 and 0.21) compared to those who switched to placebo (level 1).
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Table 7.4. Recommendations for maintenance treatment of bipolar II disorder
First line
Second line
Third line
Not recommended

Lithium, lamotrigine, quetiapinea
Divalproex; lithium or divalproex or atypical antipsychotic + antidepressant; adjunctive quetiapine a;
adjunctive lamotrigine a; combination of two of: lithium, divalproex, or atypical antipsychotic
Carbamazepine, oxcarbazepine, atypical antipsychotic agent, ECT, fluoxetine a
Gabapentin

ECT = electroconvulsive therapy.
a
New or change to recommendation.

Rates of mania ⁄ hypomania were low, and similar
for quetiapine and placebo.
Second-line options
Adjunctive lamotrigine. In a 52-week, open-label
study in 109 patients with treatment-refractory BD
II, adjunctive lamotrigine was associated with a
signiﬁcant improvement in depressive symptoms
and sustained response (level 3) (347). Depressive
symptoms continued to improve over a 52-week
period, suggesting that the two negative acutephase RCTs discussed above may have been too
short to detect a diﬀerence between lamotrigine
and placebo. Similarly, a retrospective chart review
reported that the majority of 31 patients with
treatment-resistant BD II depression who received
adjunctive lamotrigine for ‡ 6 months were much
or very much improved (348). The mean dose of
lamotrigine was 199 mg ⁄ day and the maximum
400 mg ⁄ day, suggesting that a substantial number
of patients required ‡ 200 mg for maximal beneﬁt.
Adjunctive quetiapine. Naturalistic studies in combined populations of patients with BD I and BD II
demonstrated high rates of sustained euthymia
with adjunctive quetiapine, in spite of the fact that
the quetiapine doses used in clinical practice were
substantially lower than those used in clinical trials
(level 3) (349, 350). Unfortunately, neither of these
studies reported separate results for patients with
BD II.
Third–line options
Carbamazepine ⁄ oxcarbazepine. In an RCT in BD I
(n = 27) or BD II (n = 25) patients who displayed residual manic or depressive symptoms on
maintenance lithium treatment, the addition of
eight weeks of carbamazepine or oxcarbazepine
resulted in signiﬁcant symptom reduction, with
oxcarbazepine being more eﬀective than carbamazepine (67). Results were not presented
separately for patients with BD II.
Fluoxetine monotherapy. There are now two small
RCT extension studies with ﬂuoxetine in patients

with BD II depression. The ﬁrst was a six-month
RCT in patients with BD II and BD NOS who had
responded to ﬂuoxetine, in which relapse rates were
43% with continued ﬂuoxetine versus 100% with
placebo (p = 0.08) (351). The second was a oneyear RCT (n = 81) in patients with BD II depression who had responded to ﬂuoxetine. It reported
that patients were signiﬁcantly more likely to remain
well if they continued on ﬂuoxetine than if they
switched to lithium (352). However, neither ﬂuoxetine nor lithium was signiﬁcantly better than placebo
in mean time to relapse (ﬂuoxetine 249.9 days,
lithium 156.4 days, placebo 186.9 days). The lack
of superiority of ﬂuoxetine over placebo in these
studies may be related to a lack of statistical power
due to a smaller sample size.
Data from STEP-BD and other naturalistic
studies provided additional information on the
eﬃcacy and safety of antidepressants in real-world
settings. In a STEP-BD randomized, open-label
trial, patients with depressive symptoms (n = 70;
n = 21 with BD II) who responded acutely to
adjunctive antidepressants had a signiﬁcantly longer time until relapse into depression if they
continued the antidepressant for 1–3 years versus
discontinuing after resolution of the depression
(182). Patients with BD II in this trial showed
similar beneﬁts to those with BD I, with no
increase in hypo ⁄ manic switch. Similarly, in the
entire STEP-BD sample (n = 3640; 30.7% with
BD II), there was no increased frequency of switch
from depression to hypo ⁄ mania without an intervening period of wellness in antidepressant-treated
patients (19.6%) compared to patients receiving
non-antidepressant treatments (24.9%) (353). Consistent with previous studies (354), the risk of
antidepressant-associated switch was lower in BD
II than BD I. The results from another open-label
study in patients with BD II who discontinued
antidepressant treatment showed that relapse
occurred 2.5 times more quickly when discontinuation was rapid versus gradual (355).
ECT. Information on the use of ECT in BD II
remains limited. In one small case series of 14
patients with rapid-cycling BD (nine with BD II)
who received maintenance ECT for a mean of
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21 months, all patients experienced signiﬁcant
improvement and a resolution of rapid-cycling
status (356).
Clinical questions and controversies

Is cognitive dysfunction an issue in patients with
BD II?
Persisting cognitive dysfunction is common and
debilitating in patients with BD II. In a metaanalysis, patients with BD II had lower performance scores than healthy controls in all cognitive
domains (357). In addition, cognitive impairment
in BD II was as severe as in BD I, with the
exception of memory and semantic ﬂuency.
In a case series of 58 BD I, BD II, or BD NOS
patients who received donepezil for memory problems, 84% with BD II (36 ⁄ 43) showed improvement, compared to 0% of patients with BD I (0 ⁄ 7)
and 50% of patients with BD NOS (4 ⁄ 8) (358).
More than half of the patients with BD I had
worsening of aﬀective symptoms compared to only
2% of those with BD II and 25% of those with BD
NOS.
Do the clinical features of depressive episodes inform
treatment decisions in BD II?
Data from STEP-BD show that mixed hypomanic symptoms are common during depressive
episodes, occurring in 70% of patients with BD II,
compared to 66% of patients with BD I (129).
Adjunctive antidepressants did not lead to greater
recovery rates among patients with mixed symptoms in STEP-BD, and were in fact associated with
greater manic symptom severity at the three-month
follow-up (359). Although recovery rates were not
reported separately for patients with BD II in this
sample, this suggests that antidepressants should
be avoided in BD II depressive episodes with
concomitant hypomanic symptoms.
Psychotic symptoms are also relatively common in BD II depression, and were present in
20% of patients with BD II in a Spanish study
(n = 164) (360). There is little information to
guide the treatment of psychotic depression in
patients with BD II, but clinical experience and
studies in MDD suggest that antipsychotic medications either as monotherapy (e.g., quetiapine)
or in combination with mood stabilizers may be
required.
Bipolar spectrum disorders

Diagnosis: Formulating treatment recommendations for patients with bipolar spectrum disorders
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(BSDs; also referred to as ÔBD NOSÕ in the
DSM-IV) remains hampered by both a lack of
consensus regarding which disorders should be
included in this category, and also an almost
complete absence of well-designed clinical trials in
this patient group. The issue is further compounded by uncertainty regarding the diagnostic
stability of BSDs. In fact, BSDs may be prodromal
to BD I and BD II in a substantial number of
patients, according to one longitudinal study of 57
people with cyclothymia or BD NOS, where 42%
progressed to BD II and 10% to BD I over a
4.5-year follow-up period (361).
Epidemiology: The results from two large studies
which measured the prevalence of BSDs indicate
that they are relatively common in the general
population. The World Mental Health Survey
Initiative, including 61392 people in nine countries
in North and South America, Europe, and Asia,
reported that 1.4% of the population met lifetime
criteria for subthreshold BD (4). This was similar
to the lifetime prevalence of 2.4% reported in
the National Comorbidity Survey Replication
(NCS-R) in the USA (n = 9282) (362). In both
studies, the prevalence of BSDs was greater than
those of BD I and BD II combined. The NCS-R
further suggested that BSDs are also common in
clinical populations, as over 35% of people with
major depressive episodes also met the lifetime
criteria for subthreshold hypomania (363).
Although a liberal deﬁnition of subthreshold
hypomania was utilized (lifetime presence of ‡ 1
hypomanic symptom), the NCS-R reported that,
compared to people with major depressive episodes
alone, those who had subthreshold hypomania
shared a number of clinical features with those
suﬀering from BD I or BD II, including an earlier
age of onset, more frequent depressive episodes, a
greater number of suicide attempts, and higher
rates of comorbidity.
Management: Very few studies have investigated
treatment options for BSDs. The only RCT that
has been reported to date was conducted in 56
youth with BSD or cyclothymia who were randomized to divalproex or placebo for up to
ﬁve years. At study end there were no diﬀerences
between treatment groups in time to study discontinuation due to a mood episode or for any reason,
severity of mood symptoms, or psychosocial functioning (364).
A small case series reported rapid and sustained
symptom remission in four patients with BD NOS
and depressive or mixed symptoms with lowdose quetiapine (50–75 mg) (365). In addition, a
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retrospective chart review of 34 patients with
treatment-refractory BD NOS found that adjunctive treatment with supraphysiologic doses of T3
was associated with an improvement in depressive
symptoms in 85% of patients, and remission in
38% (345). In a case series of 58 patients with BD
prescribed donepezil for memory problems, 50%
of those with BD NOS (4 ⁄ 8) had improvements in
memory; however, 25% had a worsening of aﬀective symptoms (358).
In the absence of well-designed clinical trials,
speciﬁc treatment suggestions for patients with BD
NOS cannot be made. Clinicians should formulate
treatment plans based on patientsÕ presenting
symptoms, course of illness, previous treatment
responses, and family history. Given the probability that subthreshold bipolarity is present in a
substantial proportion of patients with MDD,
clarifying the nature and best treatment options
for BD NOS is a major unmet need in mood
disorders research.

Section 8. Safety and monitoring

Monitoring

Previous iterations of the guidelines provided recommendations for initial and follow-up laboratory
investigations and monitoring strategies for patients
with BD (1–3). BD and some of its treatments can
increase the risk of comorbid medical conditions, as
well as risk factors for cardiovascular disease such
as overweight ⁄ obesity, diabetes, metabolic syndrome, and dyslipidemia. Complete medical and
laboratory investigations should be performed at
baseline, with ongoing monitoring for weight
changes and adverse eﬀects of medication.
The ISBD has also published consensus recommendations for general safety monitoring for all
BD patients receiving treatment, as well as speciﬁc
monitoring recommendations for individual
agents, and the reader is also referred to this
document for more details (366).
Unfortunately, the UNITE global survey of
1300 patients with BD found that monitoring
of safety parameters does not occur in the majority
of patients, with less than 30% undergoing weight
and blood pressure measurements, and less than
5% undergoing a physical examination or blood
tests during interactions with their principal health
care provider (11).
Safety and tolerability of pharmacotherapy for BD

The previous iterations of the guidelines have
extensively reviewed the safety and tolerability of

pharmacotherapeutic options; only new data are
included here (1–3).
An analysis of 48 RCTs in patients with BD or
schizophrenia found that, compared to risperidone,
quetiapine was associated with signiﬁcantly less
anxiety, restlessness, and extrapyramidal symptoms
(EPS); and also compared to risperidone, olanzapine was associated with increased weight gain and
ziprasidone with decreased weight gain (367).
Weight gain: The naturalistic STOP-EM trial
concluded that, in 47 patients with BD receiving
maintenance therapy following their ﬁrst manic
episode, the mean 12-month weight gain was
signiﬁcantly greater compared to healthy control
subjects (4.76 kg versus 1.50 kg; p = 0.047). In
addition, 12-month rates of overweight ⁄ obesity
were > 50% in patients with BD, almost double
those in healthy subjects (368).
A review of RCTs conﬁrmed that long-term
olanzapine treatment (‡ 48 weeks) was associated
with a substantial weight gain (mean 5.6 kg), with
64% of patients gaining ‡ 7% of their baseline
weight (369). During short-term treatment,
olanzapine orally disintegrating tablet was not
associated with any reduction in weight gain compared to the standard tablet formulation (370). By
contrast, a post-hoc analysis of a six-month RCT
found that adjunctive ziprasidone had no negative
impact on metabolic parameters or body weight
compared to adjunctive placebo (371). Post-hoc
analyses of two studies found a modest increase in
weight with adjunctive aripiprazole that was not
signiﬁcantly diﬀerent from that using lithium ⁄ divalproex alone (372). When used as an adjunct to
lamotrigine, aripiprazole plus lamotrigine was associated with an increased weight gain compared to
lamotrigine alone, which was associated with
decreased body weight over the one-year period.
The non-randomized Second-generation Antipsychotic Treatment Indications, Eﬀectiveness and
Tolerability in Youth cohort study found that after
a median of 10.8 weeks of treatment, weight
increased by 8.5 kg with olanzapine (n = 45), 6.1
kg with quetiapine (n = 36), 5.3 kg with risperidone (n = 135), and 4.4 kg with aripiprazole
(n = 41) compared to 0.2 kg in the untreated
group (n = 15) (373).
An 11-month, RCT in 50 patients on pharmacotherapy for BD found that a multimodal
lifestyle intervention (11 group sessions and weekly
ﬁtness training) signiﬁcantly reduced BMI, at end
of treatment (ﬁve months) and at a six-month
follow-up, compared to a wait-list control group;
however, the eﬀect was only signiﬁcant in women
(374).
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Metabolic syndrome and type 2 diabetes: Additional data continue to demonstrate high rates of
diabetes and metabolic syndrome associated with
atypical antipsychotic agent use in patients with
BD (375). However, in a post-hoc analysis of a sixmonth RCT, the incidence of metabolic syndrome
with aripiprazole maintenance therapy was similar
to that of placebo (376).
Additional data conﬁrm the potential for metabolic disturbances with divalproex treatment. In a
cohort study, divalproex was associated with
signiﬁcantly higher plasma insulin, triglyceride
levels, and BMI, as well as lower fasting glucose
and high-density lipoprotein cholesterol (HDL-C)
levels (377).
Dyslipidemia: Dyslipidemia is an important cardiovascular risk factor. As discussed in previous
iterations of the guidelines, atypical antipsychotic
agents, as well as lithium ⁄ divalproex, can cause
dyslipidemia (1–3). Additional data from a cohort
study found that divalproex was associated with
low HDL-C levels and high adiponectin levels in
patients with BD compared to non-psychiatric
matched control subjects (378). Lipid proﬁles
should be monitored and appropriate lipid-lowering medications prescribed as needed, according to
published recommendations for the management
of dyslipidemia.
Endocrine side eﬀects: The results from a casecontrolled study indicated higher risks of hypothyroidism in patients with BD who had used
carbamazepine alone [odds ratio (OR) = 1.68],
combination lithium and valproate (OR = 2.40),
combination lithium and carbamazepine (OR =
1.52), or all three agents (OR = 2.34) compared to
patients who had never used any of these agents
(379). A meta-analysis of 390 RCTs and observational studies found that lithium was associated with
an increased risk of clinical hypothyroidism
(OR = 5.78), as well as increases in thyroid-stimulating hormone and parathyroid hormone (380).
Suicide: A 2.5-year RCT of 98 patients with BD
and past suicide attempts found no signiﬁcant
diﬀerences between lithium and divalproex in time
to suicide attempt or suicide event, although the
trial was statistically underpowered to detect
diﬀerences (381).
Cognitive impairment: Three meta-analyses have
demonstrated persistent cognitive impairments in
euthymic patients with BD, including deﬁcits in
executive functions, verbal memory, learning,
processing speed, and attention (357, 382, 383).
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In addition, patients tested during a manic ⁄ mixed
or depressed state showed exaggerated impairment
on measures of verbal learning (383).
Several cohort studies have demonstrated greater cognitive dysfunction in euthymic patients with
BD taking antipsychotic medications compared to
healthy control subjects (384–386) or to those not
taking antipsychotic agents (385). Two cohort
studies have shown fewer cognitive impairments
associated with quetiapine than with olanzapine or
risperidone (385, 387).
An eight-week RCT in 35 euthymic patients with
BD found that adjunctive pramipexole signiﬁcantly
improved visual–verbal processing speed and
working memory compared to placebo (388).
A small (n = 16), three-month RCT in minimally
symptomatic patients with BD found that adjunctive galantamine improved episodic memory performance; however, placebo improved processing
speed (389).
Hypersensitivity and dermatological reactions:
Additional data demonstrate the risk of serious
rash, erythema multiforme, Stevens–Johnson
syndrome, or toxic epidermal necrolysis with
lamotrigine, carbamazepine, and divalproex (390,
391). A 12-week trial demonstrated a statistically
signiﬁcant reduction in the development of rashes
with a slow titration of lamotrigine compared to a
standard titration schedule (392).
The US FDA issued a warning that type I
hypersensitivity reactions (including anaphylaxis
and angioedema) can occur with asenapine use,
after as little as one dose (393).
Sedation: In a pooled analysis of data from three
short-term trials in patients with BD, asenapine
monotherapy and as an adjunct was associated
with higher rates of somnolence than placebo,
which occurred after 1–9 days of treatment and
persisted for 1–4 weeks (394).
Gastrointestinal symptoms: In a three-month RCT,
ER carbamazepine resulted in signiﬁcantly fewer
autonomic and gastrointestinal adverse events compared to the immediate-release formulation (64).
Neurological side eﬀects including EPS: An increased risk of neuroleptic malignant syndrome
associated with the use of antipsychotic medications (OR = 2.36) has been reported in patients
with BD (395).
A post-hoc analyses of pooled data in patients
with a mood disorder reported an increased rate of
akathisia in patients receiving aripiprazole (18%)
compared to placebo (5%) (396).
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Fracture risk: In a VeteranÕs Administration prospective cohort study, the use of anticonvulsants
was associated with a twofold greater risk of
fracture among patients (age ‡ 50 years) with BD
(271). In addition, a diagnosis of BD was associated with a 20% increased risk of fracture,
independent of anticonvulsant use. Antidepressants and antipsychotic agents can similarly
decrease bone mineral density (397). Screening
for bone mineral density may be indicated in highrisk populations (398).
Closing statement

The purpose of this update is to add previously
unpublished material to the CANMAT guidelines
for the treatment of BD, ensuring that they remain
current and practical. When a ﬁrst-line treatment is
unsuccessful, clinicians are advised to try alternative ﬁrst-line treatments before proceeding to
second-line options, and the same recommendation
applies when second-line treatments fail. Judicious
use of psychosocial interventions, alternative
somatic treatments such as ECT, and the numerous experimental agents oﬀer additional promise
for the management of BD.
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